BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325-340. [PMID: 29508855 DOI: 10.1038/nrclinonc.2018.29] [Cited by in Crossref: 440] [Cited by in F6Publishing: 443] [Article Influence: 110.0] [Reference Citation Analysis]
Number Citing Articles
1 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
2 Mossenta M, Busato D, Baboci L, Cintio FD, Toffoli G, Bo MD. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1086. [PMID: 31370258 DOI: 10.3390/cancers11081086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
3 Mair MJ, Ilhan-Mutlu A, Pajenda S, Kiesel B, Wöhrer A, Widhalm G, Dieckmann K, Marosi C, Wagner L, Preusser M, Berghoff AS. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunol Immunother 2021. [PMID: 33956203 DOI: 10.1007/s00262-021-02951-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu TH, Shao YY, Hsu CH. It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. J Formos Med Assoc 2021;120:1-4. [PMID: 32660891 DOI: 10.1016/j.jfma.2020.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zou H, Xia L, Jin G, Wu H, Qian W, Jia D, Xu H, Li T. Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study. CMAR 2022;Volume 14:1703-11. [DOI: 10.2147/cmar.s357334] [Reference Citation Analysis]
6 Xu C, Liu D, Chen Z, Zhuo F, Sun H, Hu J, Li T. Umbilical Cord Blood-Derived Natural Killer Cells Combined with Bevacizumab for Colorectal Cancer Treatment. Hum Gene Ther 2019;30:459-70. [PMID: 29914273 DOI: 10.1089/hum.2018.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Bai R, Cui J. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. Front Immunol 2022;13:890166. [DOI: 10.3389/fimmu.2022.890166] [Reference Citation Analysis]
8 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Samaha H, Pignata A, Fousek K, Ren J, Lam FW, Stossi F, Dubrulle J, Salsman VS, Krishnan S, Hong SH, Baker ML, Shree A, Gad AZ, Shum T, Fukumura D, Byrd TT, Mukherjee M, Marrelli SP, Orange JS, Joseph SK, Sorensen PH, Taylor MD, Hegde M, Mamonkin M, Jain RK, El-Naggar S, Ahmed N. A homing system targets therapeutic T cells to brain cancer. Nature 2018;561:331-7. [PMID: 30185905 DOI: 10.1038/s41586-018-0499-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
10 Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
11 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Reference Citation Analysis]
12 Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin 2022. [PMID: 35927312 DOI: 10.1038/s41401-022-00953-z] [Reference Citation Analysis]
13 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
14 Liu N, Liu M, Fu S, Wang J, Tang H, Isah AD, Chen D, Wang X. Ang2-Targeted Combination Therapy for Cancer Treatment. Front Immunol 2022;13:949553. [DOI: 10.3389/fimmu.2022.949553] [Reference Citation Analysis]
15 Ribeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco Miguel M. Tumor microenvironment components: Allies of cancer progression. Pathol Res Pract 2020;216:152729. [PMID: 31735322 DOI: 10.1016/j.prp.2019.152729] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
16 Hu J, Wang Z, Chen Z, Li A, Sun J, Zheng M, Wu J, Shen T, Qiao J, Li L, Li B, Wu D, Xiao Q. DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer. Biomed Pharmacother 2020;127:110229. [PMID: 32559853 DOI: 10.1016/j.biopha.2020.110229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Cignarella A, Fadini GP, Bolego C, Trevisi L, Boscaro C, Sanga V, Seccia TM, Rosato A, Rossi GP, Barton M. Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. Cardiovasc Res 2021:cvab096. [PMID: 33739385 DOI: 10.1093/cvr/cvab096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ju S, Zhou C, Yang C, Wang C, Liu J, Wang Y, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Front Oncol 2022;11:835889. [DOI: 10.3389/fonc.2021.835889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 2019;154:21-31. [PMID: 30453028 DOI: 10.1016/j.ymeth.2018.11.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
20 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 62.0] [Reference Citation Analysis]
21 Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol 2018;52:107-16. [PMID: 29935312 DOI: 10.1016/j.semcancer.2018.06.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
22 Jin X, Liu Z, Yang D, Yin K, Chang X. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Front Immunol 2022;13:948647. [DOI: 10.3389/fimmu.2022.948647] [Reference Citation Analysis]
23 Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:3059-67. [PMID: 33811482 DOI: 10.1002/cam4.3880] [Reference Citation Analysis]
24 Bokas A, Papakotoulas P, Sarantis P, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. Cancers (Basel) 2020;12:E432. [PMID: 32069809 DOI: 10.3390/cancers12020432] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gao X, McDermott DF, Michaelson MD. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? Oncologist 2019;24:725-7. [PMID: 31036769 DOI: 10.1634/theoncologist.2019-0165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh SW, Bergan R, Liu Y, Liu Y. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer. Clin Breast Cancer 2020;20:291-299.e3. [PMID: 32482525 DOI: 10.1016/j.clbc.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Taleb M, Atabakhshi-Kashi M, Wang Y, Rezvani Alanagh H, Farhadi Sabet Z, Li F, Cheng K, Li C, Qi Y, Nie G, Ying Z. Bifunctional Therapeutic Peptide Assembled Nanoparticles Exerting Improved Activities of Tumor Vessel Normalization and Immune Checkpoint Inhibition. Adv Healthc Mater 2021;10:e2100051. [PMID: 34021735 DOI: 10.1002/adhm.202100051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
28 Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines 2021;9:835. [PMID: 34356899 DOI: 10.3390/biomedicines9070835] [Reference Citation Analysis]
29 Wang X, Xu W, Chi Z, Si L, Sheng X, Kong Y, Zhou L, Mao L, Lian B, Tang B, Yan X, Bai X, Cui C, Guo J. Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Transl Oncol 2021;14:100949. [PMID: 33221685 DOI: 10.1016/j.tranon.2020.100949] [Reference Citation Analysis]
30 Wang C, Chen Y, Wang Y, Liu X, Liu Y, Li Y, Chen H, Fan C, Wu D, Yang J. Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1. J Exp Clin Cancer Res 2019;38:371. [PMID: 31438982 DOI: 10.1186/s13046-019-1361-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
31 Ayoub NM, Jaradat SK, Al-shami KM, Alkhalifa AE. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Front Pharmacol 2022;13:838133. [DOI: 10.3389/fphar.2022.838133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Fridman WH, Miller I, Sautès-Fridman C, Byrne AT. Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology 2020;158:303-21. [PMID: 31622621 DOI: 10.1053/j.gastro.2019.09.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
33 Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, Lambaudie E, Olive D, Sabatier R. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. Biomedicines 2021;9:632. [PMID: 34199461 DOI: 10.3390/biomedicines9060632] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Ann Transl Med 2020;8:1095. [PMID: 33145314 DOI: 10.21037/atm-20-3735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Arora S, Rastogi S, Shamim SA, Barwad A, Sethi M. Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report. Clin Sarcoma Res 2020;10:10. [PMID: 32670543 DOI: 10.1186/s13569-020-00133-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Chen J, Rong X, Liu X, Zheng D, Rong X, Chen F, Zhao P, Liu F, Ruan J. FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell Int 2020;20:196. [PMID: 32508532 DOI: 10.1186/s12935-020-01265-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Dalgleish AG, Stern PL. The failure of radical treatments to cure cancer: can less deliver more? Ther Adv Vaccines Immunother 2018;6:69-76. [PMID: 30623172 DOI: 10.1177/2515135518815393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Riddiough GE, Fifis T, Muralidharan V, Perini MV, Christophi C. Searching for the link; mechanisms underlying liver regeneration and recurrence of colorectal liver metastasis post partial hepatectomy. J Gastroenterol Hepatol 2019;34:1276-86. [PMID: 30828863 DOI: 10.1111/jgh.14644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Fu Y, Peng Y, Zhao S, Mou J, Zeng L, Jiang X, Yang C, Huang C, Li Y, Lu Y, Wu M, Yang Y, Kong T, Lai Q, Wu Y, Yao Y, Wang Y, Gou L, Yang J. Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma. Front Cell Dev Biol 2021;9:689727. [PMID: 34307367 DOI: 10.3389/fcell.2021.689727] [Reference Citation Analysis]
40 Yang L, Hao X, Hu X, Wang Z, Yang K, Mi Y, Yang Y, Xu H, Yang G, Wang Y. Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thorac Cancer 2020;11:3501-9. [PMID: 33075201 DOI: 10.1111/1759-7714.13689] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zhu L, Yu X, Wang L, Liu J, Qu Z, Zhang H, Li L, Chen J, Zhou Q. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges. Oncogenesis 2021;10:47. [PMID: 34247198 DOI: 10.1038/s41389-021-00335-w] [Reference Citation Analysis]
42 Geraldo LH, Xu Y, Jacob L, Pibouin-Fragner L, Rao R, Maissa N, Verreault M, Lemaire N, Knosp C, Lesaffre C, Daubon T, Dejaegher J, Solie L, Rudewicz J, Viel T, Tavitian B, De Vleeschouwer S, Sanson M, Bikfalvi A, Idbaih A, Lu QR, Lima FR, Thomas JL, Eichmann A, Mathivet T. SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. J Clin Invest 2021;131:141083. [PMID: 34181595 DOI: 10.1172/JCI141083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zeng Z, Pu K. Improving Cancer Immunotherapy by Cell Membrane‐Camouflaged Nanoparticles. Adv Funct Mater 2020;30:2004397. [DOI: 10.1002/adfm.202004397] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 32.0] [Reference Citation Analysis]
44 Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer 2019;19:667-85. [PMID: 31645711 DOI: 10.1038/s41568-019-0209-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
45 Fejza A, Polano M, Camicia L, Poletto E, Carobolante G, Toffoli G, Mongiat M, Andreuzzi E. The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2. Int J Mol Sci 2021;22:7511. [PMID: 34299131 DOI: 10.3390/ijms22147511] [Reference Citation Analysis]
46 Kamal N, Ilowefah MA, Hilles AR, Anua NA, Awin T, Alshwyeh HA, Aldosary SK, Jambocus NGS, Alosaimi AA, Rahman A, Mahmood S, Mediani A. Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention. Molecules 2022;27:1794. [PMID: 35335158 DOI: 10.3390/molecules27061794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Shiono A, Miura Y, Murayama Y, Kobayashi K, Kagamu H, Kuji I. Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50. Sci Rep 2020;10:14990. [PMID: 32929123 DOI: 10.1038/s41598-020-71735-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 McDowell SAC, Quail DF. Immunological Regulation of Vascular Inflammation During Cancer Metastasis. Front Immunol 2019;10:1984. [PMID: 31497019 DOI: 10.3389/fimmu.2019.01984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 He Y, Liu T, Dai S, Xu Z, Wang L, Luo F. Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy? Front Cell Dev Biol 2021;9:739161. [PMID: 34733848 DOI: 10.3389/fcell.2021.739161] [Reference Citation Analysis]
50 Kong F, Wang Z, Liao D, Zuo J, Xie H, Li X, Jia Y. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. Front Oncol 2021;11:739191. [PMID: 34532293 DOI: 10.3389/fonc.2021.739191] [Reference Citation Analysis]
51 Gao L, Yang X, Yi C, Zhu H. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Front Pharmacol 2019;10:1173. [PMID: 31680957 DOI: 10.3389/fphar.2019.01173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
52 Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther 2022. [PMID: 35260027 DOI: 10.1080/14737140.2022.2039123] [Reference Citation Analysis]
53 Fu Y, Liu J, Jiang Y. Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report. Front Endocrinol 2022;13:810747. [DOI: 10.3389/fendo.2022.810747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Chen Q, Liu L, Lu Y, Chen X, Zhang Y, Zhou W, Guo Q, Li C, Zhang Y, Zhang Y, Liang D, Sun T, Jiang C. Tumor Microenvironment-Triggered Aggregated Magnetic Nanoparticles for Reinforced Image-Guided Immunogenic Chemotherapy. Adv Sci (Weinh) 2019;6:1802134. [PMID: 30937276 DOI: 10.1002/advs.201802134] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
55 Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A. Cabozantinib for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2019;19:847-55. [PMID: 31603008 DOI: 10.1080/14737140.2019.1674141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
56 Chen L, Tong F, Peng L, Huang Y, Yin P, Feng Y, Cheng S, Wang J, Dong X. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. Radiother Oncol 2022:S0167-8140(22)04183-4. [PMID: 35788355 DOI: 10.1016/j.radonc.2022.06.022] [Reference Citation Analysis]
57 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
58 Martínez-Rey D, Carmona-Rodríguez L, Fernández-Aceñero MJ, Mira E, Mañes S. Extracellular Superoxide Dismutase, the Endothelial Basement Membrane, and the WNT Pathway: New Players in Vascular Normalization and Tumor Infiltration by T-Cells. Front Immunol 2020;11:579552. [PMID: 33250894 DOI: 10.3389/fimmu.2020.579552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yang S, Chen C, Qiu Y, Xu C, Yao J. Paying attention to tumor blood vessels: Cancer phototherapy assisted with nano delivery strategies. Biomaterials 2021;268:120562. [PMID: 33278682 DOI: 10.1016/j.biomaterials.2020.120562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018;15:422-42. [DOI: 10.1038/s41571-018-0003-5] [Cited by in Crossref: 332] [Cited by in F6Publishing: 320] [Article Influence: 83.0] [Reference Citation Analysis]
61 Morikawa A, Grkovski M, Patil S, Jhaveri KL, Tang K, Humm JL, Holodny A, Beal K, Schöder H, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Res Treat 2021;188:415-25. [PMID: 34109515 DOI: 10.1007/s10549-021-06209-4] [Reference Citation Analysis]
62 Perdrizet K, Leighl NB. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Curr Treat Options Oncol 2019;20:21. [PMID: 30778772 DOI: 10.1007/s11864-019-0617-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
63 Lv P, Chen X, Fu S, Ren E, Liu C, Liu X, Jiang L, Zeng Y, Wang X, Liu G. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy. Biomater Sci 2021;9:7392-401. [PMID: 34751685 DOI: 10.1039/d1bm00928a] [Reference Citation Analysis]
64 Sun X, Zhang Q, Mei J, Yang Z, Chen M, Liang T. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09405-7] [Reference Citation Analysis]
65 Dai Z, Liu T, Liu G, Deng Z, Yu P, Wang B, Cen B, Guo L, Zhang J. Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma. Front Mol Biosci 2021;8:757421. [PMID: 34869590 DOI: 10.3389/fmolb.2021.757421] [Reference Citation Analysis]
66 Sové RJ, Jafarnejad M, Zhao C, Wang H, Ma H, Popel AS. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications. CPT Pharmacometrics Syst Pharmacol 2020;9:484-97. [PMID: 32618119 DOI: 10.1002/psp4.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
67 Gao B, Feng C, Chai F, Wei S, Hong N, Ye Y, Wang Y, Cheng J. CT-detected extramural venous invasion-related gene signature for the overall survival prediction in patients with gastric cancer. Cancer Med 2021;10:7816-30. [PMID: 34510798 DOI: 10.1002/cam4.4266] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer 2020;19:19. [PMID: 32000802 DOI: 10.1186/s12943-020-1144-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 25.5] [Reference Citation Analysis]
69 Fares J, Ulasov I, Timashev P, Lesniak MS. Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. Brain 2021;144:1046-66. [PMID: 33893488 DOI: 10.1093/brain/awab012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology 2020;9:1760685. [PMID: 32923118 DOI: 10.1080/2162402X.2020.1760685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
72 Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020;72:342-352. [PMID: 31954496 DOI: 10.1016/j.jhep.2019.09.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 90.0] [Reference Citation Analysis]
73 Isla D, de Castro J, García-campelo R, Lianes P, Felip E, Garrido P, Paz-ares L, Trigo JM. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol 2020;22:759-71. [DOI: 10.1007/s12094-019-02191-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
74 Jin S, Zeng H, Liu Z, Jin K, Liu C, Yan S, Yu Y, You R, Zhang H, Chang Y, Xu L, Xu J, Wang Z, Zhu Y. Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11155-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Yang Y, Li L, Jiang Z, Wang B, Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 2020;69:2523-32. [PMID: 32577817 DOI: 10.1007/s00262-020-02641-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
76 Wainsztein VE, Chen TW. When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. Journal of Immunotherapy and Precision Oncology 2020;3:69-82. [DOI: 10.36401/jipo-19-37] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Du Y, Qi Y, Jin Z, Tian J. Noninvasive imaging in cancer immunotherapy: The way to precision medicine. Cancer Letters 2019;466:13-22. [DOI: 10.1016/j.canlet.2019.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
78 Solimando AG, Annese T, Tamma R, Ingravallo G, Maiorano E, Vacca A, Specchia G, Ribatti D. New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers (Basel) 2020;12:E1869. [PMID: 32664527 DOI: 10.3390/cancers12071869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
79 Gaspar N, Campbell-Hewson Q, Huang J, Okpara CE, Bautista F. OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. Future Oncol 2021. [PMID: 34382412 DOI: 10.2217/fon-2021-0743] [Reference Citation Analysis]
80 Hah YS, Koo KC. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci 2021;22:4452. [PMID: 33923219 DOI: 10.3390/ijms22094452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
81 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
82 Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol 2020;21:e419-30. [PMID: 32888471 DOI: 10.1016/S1470-2045(20)30234-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
83 Lei Y, Zhao S, Jiang M. Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. Front Immunol 2021;12:653319. [PMID: 34566950 DOI: 10.3389/fimmu.2021.653319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
84 Xu W, Wang K, Gu W, Nie X, Zhang H, Tang C, Lin L, Liang J. Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma. Front Oncol 2022;12:809068. [PMID: 35311098 DOI: 10.3389/fonc.2022.809068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Cheng Y, Li H, Zhang L, Liu JJ, Yang CL, Zhang S. Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chin Med J (Engl) 2021;134:1780-8. [PMID: 34133356 DOI: 10.1097/CM9.0000000000001560] [Reference Citation Analysis]
86 Bannoud N, Dalotto-Moreno T, Kindgard L, García PA, Blidner AG, Mariño KV, Rabinovich GA, Croci DO. Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells. Front Immunol 2021;12:660944. [PMID: 34025660 DOI: 10.3389/fimmu.2021.660944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, Shamseddine A. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Int J Mol Sci 2021;22:2142. [PMID: 33670011 DOI: 10.3390/ijms22042142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
88 Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:420-435. [PMID: 30718072 DOI: 10.1016/s1470-2045(18)30791-5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 48] [Article Influence: 26.7] [Reference Citation Analysis]
89 Lin X, Qiu G, Li F, Deng H, Qin Y, Xie X, Jiang J, Song Y, Liu M, Zhou C. Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy. Front Immunol 2021;12:683202. [PMID: 34149722 DOI: 10.3389/fimmu.2021.683202] [Reference Citation Analysis]
90 Meng N, Xie H, Hou J, Chen Y, Wu M, Guo Y, Jiang C. Design and semisynthesis of oleanolic acid derivatives as VEGF inhibitors: Inhibition of VEGF-induced proliferation, angiogenesis, and VEGFR2 activation in HUVECs. Chinese Journal of Natural Medicines 2022;20:229-40. [DOI: 10.1016/s1875-5364(22)60159-6] [Reference Citation Analysis]
91 Choi SH, Yoo SS, Lee SY, Park JY. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharm Res 2022. [PMID: 35449345 DOI: 10.1007/s12272-022-01382-6] [Reference Citation Analysis]
92 Qi S, Deng S, Lian Z, Yu K. Novel Drugs with High Efficacy against Tumor Angiogenesis. IJMS 2022;23:6934. [DOI: 10.3390/ijms23136934] [Reference Citation Analysis]
93 Fan Z, Liu H, Xue Y, Lin J, Fu Y, Xia Z, Pan D, Zhang J, Qiao K, Zhang Z, Liao Y. Reversing cold tumors to hot: An immunoadjuvant-functionalized metal-organic framework for multimodal imaging-guided synergistic photo-immunotherapy. Bioact Mater. 2021;6:312-325. [PMID: 32954050 DOI: 10.1016/j.bioactmat.2020.08.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
94 Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Martin JD, Seano G, Jain RK. Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. Annu Rev Physiol 2019;81:505-34. [PMID: 30742782 DOI: 10.1146/annurev-physiol-020518-114700] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 58.5] [Reference Citation Analysis]
96 He B, Ganss R. Modulation of the Vascular-Immune Environment in Metastatic Cancer. Cancers (Basel) 2021;13:810. [PMID: 33671981 DOI: 10.3390/cancers13040810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Liu Y, Feng M, Chen H, Yang G, Qiu J, Zhao F, Cao Z, Luo W, Xiao J, You L, Zheng L, Zhang T. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Lett 2020;485:1-13. [PMID: 32428662 DOI: 10.1016/j.canlet.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Xiao G, Gao X, Li L, Liu C, Liu Z, Peng H, Xia X, Yi X, Zhou R. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. J Oncol 2021;2021:3766685. [PMID: 34961815 DOI: 10.1155/2021/3766685] [Reference Citation Analysis]
99 You B, Pan S, Gu M, Zhang K, Xia T, Zhang S, Chen W, Xie H, Fan Y, Yao H, Cheng T, Zhang P, Liu D, You Y. Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation. J Extracell Vesicles 2022;11:e12221. [PMID: 35524442 DOI: 10.1002/jev2.12221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Chen H, Dai Z. Antitumor immune responses induced by photodynamic and sonodynamic therapy: a narrative review. Journal of Bio-X Research 2021;4:77-86. [DOI: 10.1097/jbr.0000000000000080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
101 Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer 2018;119:1171-81. [PMID: 30393372 DOI: 10.1038/s41416-018-0258-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 16.5] [Reference Citation Analysis]
102 Chen Y, Xia F, Jiang B, Wang W, Li X. Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer. Front Med (Lausanne) 2021;8:674338. [PMID: 34513864 DOI: 10.3389/fmed.2021.674338] [Reference Citation Analysis]
103 Wan X, Song M, Wang A, Zhao Y, Wei Z, Lu Y. Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy. Front Immunol 2021;12:747914. [PMID: 34745119 DOI: 10.3389/fimmu.2021.747914] [Reference Citation Analysis]
104 Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2019;25:80-9. [PMID: 30190369 DOI: 10.1158/1078-0432.CCR-18-0847] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
105 Shi LZ, Bonner JA. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis. Int J Mol Sci 2021;22:12295. [PMID: 34830176 DOI: 10.3390/ijms222212295] [Reference Citation Analysis]
106 Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Demetriou P, Pierides C, Polydorou C, Stylianou A, Louca M, Koumas L, Costeas P, Kataoka K, Cabral H, Stylianopoulos T. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics 2020;10:1910-22. [PMID: 32042344 DOI: 10.7150/thno.36936] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 24.5] [Reference Citation Analysis]
107 Tian BR, Lin WF, Zhang Y. Effects of biomechanical forces on the biological behavior of cancer stem cells. J Cancer 2021;12:5895-902. [PMID: 34476003 DOI: 10.7150/jca.60893] [Reference Citation Analysis]
108 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Reference Citation Analysis]
109 Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers (Basel) 2021;13:4438. [PMID: 34503248 DOI: 10.3390/cancers13174438] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int J Mol Sci 2020;21:E5840. [PMID: 32823989 DOI: 10.3390/ijms21165840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
111 Li J, Wang H, Wang Y, Gong X, Xu X, Sha X, Zhang A, Zhang Z, Li Y. Tumor-Activated Size-Enlargeable Bioinspired Lipoproteins Access Cancer Cells in Tumor to Elicit Anti-Tumor Immune Responses. Adv Mater 2020;32:e2002380. [PMID: 33252171 DOI: 10.1002/adma.202002380] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
112 Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. J Ovarian Res 2021;14:112. [PMID: 34454562 DOI: 10.1186/s13048-021-00862-5] [Reference Citation Analysis]
113 Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJ, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon J, Besse B, Besse B, Lacas B, Pignon J, Remon J, Berghmans T, Dahlberg S, Felip E, Berghmans T, Besse B, Dahlberg S, Felip E, Garon E, Groen HJ, Hanna N, Heist RS, Herbst R, Heymach JV, Lacas B, Adjei AA, Heist R, Mandrekar SJ, Neal JW, Okamoto I, Pignon J, Ramlau R, Remon J, Reck M, Scagliotti GV, Vansteenkiste J, Yoh K. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer 2022;166:112-25. [DOI: 10.1016/j.ejca.2022.02.002] [Reference Citation Analysis]
114 Bejjani AC, Finn RS. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol 2022;:JCO2102605. [PMID: 35649192 DOI: 10.1200/JCO.21.02605] [Reference Citation Analysis]
115 Li X, Wang L, Chen S, Zhou F, Zhao J, Zhao W, Su C. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 2020;11:2812-9. [PMID: 32779372 DOI: 10.1111/1759-7714.13597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science 2019;365:544-5. [PMID: 31395771 DOI: 10.1126/science.aaw7875] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 27.5] [Reference Citation Analysis]
117 Zhao S, Xu B, Ma W, Chen H, Jiang C, Cai J, Meng X. DNA Damage Repair in Brain Tumor Immunotherapy. Front Immunol 2021;12:829268. [PMID: 35095931 DOI: 10.3389/fimmu.2021.829268] [Reference Citation Analysis]
118 Doi T, Fujiwara Y, Shitara K, Shimizu T, Yonemori K, Matsubara N, Ohno I, Kogawa T, Naito Y, Leopold L, Munteanu M, Yatsuzuka N, Han SR, Samkari A, Yamamoto N. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Invest New Drugs 2021;39:152-62. [PMID: 32564277 DOI: 10.1007/s10637-020-00942-1] [Reference Citation Analysis]
119 Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, Liu R, Zhang Y, Li Y, Yin G, Guan Y, Xia X, Yi X, Xu J. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. Clin Transl Oncol 2021;23:1646-56. [PMID: 33583004 DOI: 10.1007/s12094-021-02562-4] [Reference Citation Analysis]
120 Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther 2021;219:107694. [PMID: 32980443 DOI: 10.1016/j.pharmthera.2020.107694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
121 Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 2020;11:309. [PMID: 32366856 DOI: 10.1038/s41419-020-2511-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
122 Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse E, De Palma M, Zippelius A. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci U S A 2020;117:541-51. [PMID: 31889004 DOI: 10.1073/pnas.1902145116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
123 Qiu L, Ning H, Zhu Y, Yang Q, Liu L, Luo L, Gao Y, Xing Y. Feedback regulation of antioxidant transcription factor NFE2L1 and immunostimulatory factor 41BBL mediates the crosstalk between oxidative stress and tumor immunity. Mol Immunol 2021;141:265-72. [PMID: 34902807 DOI: 10.1016/j.molimm.2021.12.001] [Reference Citation Analysis]
124 Zhang T, Jia Y, Yu Y, Zhang B, Xu F, Guo H. Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy. Adv Drug Deliv Rev 2022;186:114319. [PMID: 35545136 DOI: 10.1016/j.addr.2022.114319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, Dong X. Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer. Adv Mater 2021;33:e2005155. [PMID: 33684242 DOI: 10.1002/adma.202005155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
126 Zheng R, Li F, Li F, Gong A. Targeting tumor vascularization: promising strategies for vascular normalization. J Cancer Res Clin Oncol 2021;147:2489-505. [PMID: 34148156 DOI: 10.1007/s00432-021-03701-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Reference Citation Analysis]
128 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 He C, Yu L, Ding L, Chen Y, Hao Y. Self‐Assembled/Drug‐Composed Nanomedicine for Synergistic Photonic Hyperthermia and Targeted Therapy of Breast Cancer by Inhibiting ERK, AKT, and STAT3 Signaling Cascades. Adv Funct Mater 2020;30:1908907. [DOI: 10.1002/adfm.201908907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
130 Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncology 2021;17:1943-61. [DOI: 10.2217/fon-2020-1103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
131 Schmitt M, Sinnberg T, Niessner H, Forschner A, Garbe C, Macek B, Nalpas NC. Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers (Basel) 2021;13:5411. [PMID: 34771574 DOI: 10.3390/cancers13215411] [Reference Citation Analysis]
132 Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel) 2021;13:2429. [PMID: 34069772 DOI: 10.3390/cancers13102429] [Reference Citation Analysis]
133 Stylianopoulos T, Munn LL, Jain RK. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer 2018;4:292-319. [PMID: 29606314 DOI: 10.1016/j.trecan.2018.02.005] [Cited by in Crossref: 183] [Cited by in F6Publishing: 151] [Article Influence: 45.8] [Reference Citation Analysis]
134 Zhong W, Wu Y, Zhu M, Zhong H, Huang C, Lin Y, Huang J. Alternative splicing and alternative polyadenylation define tumor immune microenvironment and pharmacogenomic landscape in clear cell renal carcinoma. Mol Ther Nucleic Acids 2022;27:927-46. [PMID: 35211354 DOI: 10.1016/j.omtn.2022.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Abou Khouzam R, Goutham HV, Zaarour RF, Chamseddine AN, Francis A, Buart S, Terry S, Chouaib S. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Semin Cancer Biol 2020;65:140-54. [PMID: 31927131 DOI: 10.1016/j.semcancer.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
136 Wu J, Zhang Y, Ye L, Wang C. The anti-cancer effects and mechanisms of lactic acid bacteria exopolysaccharides in vitro: A review. Carbohydr Polym 2021;253:117308. [PMID: 33278957 DOI: 10.1016/j.carbpol.2020.117308] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
137 Li TJ, Wang WQ, Yu XJ, Liu L. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2020;1874:188384. [PMID: 32531324 DOI: 10.1016/j.bbcan.2020.188384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Offin M, Rusch VW, Rimner A, Adusumilli PS, Zauderer MG. Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. Oncologist 2022:oyac113. [PMID: 35708504 DOI: 10.1093/oncolo/oyac113] [Reference Citation Analysis]
139 Fu R, Li Y, Jiang N, Ren BX, Zang CZ, Liu LJ, Lv WC, Li HM, Weiss S, Li ZY, Lu T, Wu ZQ. Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies. J Clin Invest 2020;130:1252-70. [PMID: 32039918 DOI: 10.1172/JCI131507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Liu Y, Zhang T, Zhang L, Zhao C, Zhang Z, Wang Z, Gu M, Li W, Li B. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer. Immunotherapy 2022. [PMID: 35574588 DOI: 10.2217/imt-2021-0196] [Reference Citation Analysis]
141 He X, Qu Y, Lin X, Sun J, Jiang Z, Wang C, Deng Y, Yan F, Sun Y. Self-assembled D-arginine derivatives based on click chemical reactions for intracellular codelivery of antigens and adjuvants for potential immunotherapy. J Mater Chem B 2022;10:3491-500. [PMID: 35403659 DOI: 10.1039/d2tb00346e] [Reference Citation Analysis]
142 Sasaki R, Nagata K, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Soyama A, Hidaka M, Eguchi S, Shigeno M, Yamashima M, Yamamichi S, Ichikawa T, Kugiyama Y, Yatsuhashi H, Nakao K. Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. Cancers 2022;14:827. [DOI: 10.3390/cancers14030827] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Ganss R. Tumour vessel remodelling: new opportunities in cancer treatment. Vasc Biol 2020;2:R35-43. [PMID: 32923973 DOI: 10.1530/VB-19-0032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
144 Katoh M. Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. J Thorac Dis 2018;10:5178-83. [PMID: 30416762 DOI: 10.21037/jtd.2018.08.123] [Reference Citation Analysis]
145 Passiglia F, Reale ML, Cetoretta V, Novello S. Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? Immunotargets Ther 2021;10:9-26. [PMID: 33575224 DOI: 10.2147/ITT.S253581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Tu B, He Y, Chen B, Wang Y, Gao Y, Shi M, Liu T, Asrorov AM, Huang Y. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomater Sci 2020;8:7166-76. [PMID: 33169732 DOI: 10.1039/d0bm01516d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Drobni ZD, Michielin O, Quinaglia T, Zlotoff DA, Zubiri L, Gilman HK, Supraja S, Merkely B, Muller V, Sullivan RJ, Reynolds KL, Pittet MJ, Jain RK, Neilan TG. Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. European Journal of Cancer 2022;163:108-18. [DOI: 10.1016/j.ejca.2021.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
148 Solimando AG, Summa S, Vacca A, Ribatti D. Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers (Basel) 2020;12:E3380. [PMID: 33203154 DOI: 10.3390/cancers12113380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
149 Ren M, Zheng X, Gao H, Jiang A, Yao Y, He W. Nanomedicines Targeting Metabolism in the Tumor Microenvironment. Front Bioeng Biotechnol 2022;10:943906. [DOI: 10.3389/fbioe.2022.943906] [Reference Citation Analysis]
150 Chen W, Pan X, Cui X. RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe? Front Oncol 2020;10:573690. [PMID: 33117708 DOI: 10.3389/fonc.2020.573690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Xu C, Yang S, Jiang Z, Zhou J, Yao J. Self-Propelled Gemini-like LMWH-Scaffold Nanodrugs for Overall Tumor Microenvironment Manipulation via Macrophage Reprogramming and Vessel Normalization. Nano Lett 2020;20:372-83. [DOI: 10.1021/acs.nanolett.9b04024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
152 Chen Y, Song W, Shen L, Qiu N, Hu M, Liu Y, Liu Q, Huang L. Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors. ACS Nano 2019;13:1751-63. [PMID: 30642161 DOI: 10.1021/acsnano.8b07830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
153 He Q, Zhang Z, Liu H, Tuo Z, Zhou J, Hu Y, Sun Y, Wan C, Xu Z, Lovell JF, Hu D, Yang K, Jin H. Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery. Nanoscale 2020;12:14788-800. [DOI: 10.1039/d0nr02750b] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
154 Zou W, Qian C, Zhang S, Wan X, Wei Z, Li X, Wu Y, Chen W, Wang A, Zhao Y, Lu Y. Targeting the Ang2/Tie2 Axis with Tanshinone IIA Elicits Vascular Normalization in Ischemic Injury and Colon Cancer. Oxid Med Cell Longev 2021;2021:7037786. [PMID: 34804370 DOI: 10.1155/2021/7037786] [Reference Citation Analysis]
155 Chen C, Tang Y, Huang H, Jia L, Feng L, Zhao J, Zhang H, He J, Ding L, Xia D. Relieving immunosuppression by Endo@PLT targeting anti-angiogenesis to improve the efficacy of immunotherapies. Chem Commun (Camb) 2022;58:3202-5. [PMID: 35174839 DOI: 10.1039/d2cc00205a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol 2019;20:837-48. [PMID: 31078463 DOI: 10.1016/S1470-2045(19)30153-6] [Cited by in Crossref: 97] [Cited by in F6Publishing: 59] [Article Influence: 32.3] [Reference Citation Analysis]
157 Wei Y, Du Q, Jiang X, Li L, Li T, Li M, Fan X, Li Y, Kariminia S, Li Q. Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2019;138:178-89. [DOI: 10.1016/j.critrevonc.2019.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
158 Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Boeck S. Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opin Investig Drugs 2022. [PMID: 35114868 DOI: 10.1080/13543784.2022.2037552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Hochmair MJ, Kolb R, Wurm R, Zach H, Bittner N. Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series. Case Rep Oncol 2022;15:138-48. [PMID: 35350799 DOI: 10.1159/000520939] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chang M, Dong C, Huang H, Ding L, Feng W, Chen Y. Nanobiomimetic Medicine. Adv Funct Materials. [DOI: 10.1002/adfm.202204791] [Reference Citation Analysis]
161 Gordon B, Gadi VK. The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines (Basel) 2020;8:E529. [PMID: 32937885 DOI: 10.3390/vaccines8030529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Ther Adv Med Oncol 2020;12:1758835920937902. [PMID: 32670423 DOI: 10.1177/1758835920937902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
163 Konstantinopoulos PA, Cannistra SA. Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality? J Clin Oncol 2021;39:1833-8. [PMID: 33891471 DOI: 10.1200/JCO.21.00571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
164 Xiang J, Zhang Y, Liu X, Zhou Q, Piao Y, Shao S, Tang J, Zhou Z, Xie T, Shen Y. Natural Polyphenols-Platinum Nanocomplexes Stimulate Immune System for Combination Cancer Therapy. Nano Lett 2022. [PMID: 35749341 DOI: 10.1021/acs.nanolett.2c02161] [Reference Citation Analysis]
165 Personeni N, Pressiani T, D'Alessio A, Prete MG, Bozzarelli S, Terracciano L, Dal Buono A, Capogreco A, Aghemo A, Lleo A, Lutman RF, Roncalli M, Giordano L, Santoro A, Di Tommaso L, Rimassa L. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:5665. [PMID: 34830823 DOI: 10.3390/cancers13225665] [Reference Citation Analysis]
166 Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs 2022. [PMID: 35477812 DOI: 10.1007/s10637-022-01248-0] [Reference Citation Analysis]
167 Mukherji R, Weinberg BA, Pedersen KS. Immunotherapy for Colorectal Cancer. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2022.02.010] [Reference Citation Analysis]
168 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
169 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
170 Évrard S, Pernot S, Khatib M. [Sequential therapeutic strategy: Promises and difficulties]. Bull Cancer 2021;108:443-5. [PMID: 33845993 DOI: 10.1016/j.bulcan.2021.02.005] [Reference Citation Analysis]
171 Wang Q, Li P, Wu W. A systematic analysis of immune genes and overall survival in cancer patients. BMC Cancer 2019;19:1225. [PMID: 31842801 DOI: 10.1186/s12885-019-6414-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
172 Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Ther Targets 2021;25:153-62. [PMID: 33502260 DOI: 10.1080/14728222.2021.1882998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book 2019;39:165-74. [PMID: 31099649 DOI: 10.1200/EDBK_237987] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 19.7] [Reference Citation Analysis]
174 Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, Lin Z, Chen L, Gong Y, Zhu J, Zhou Q, Huang M, Lu Y. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. Front Oncol 2021;11:739090. [PMID: 34888234 DOI: 10.3389/fonc.2021.739090] [Reference Citation Analysis]
175 Liao Y, Wu X, Wu M, Fang Y, Li J, Tang W. Non-coding RNAs in lung cancer: emerging regulators of angiogenesis. J Transl Med 2022;20:349. [PMID: 35918758 DOI: 10.1186/s12967-022-03553-x] [Reference Citation Analysis]
176 Aspeslagh S, Chabanon RM, Champiat S, Postel-vinay S. Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology 2020;65:123-39. [DOI: 10.1016/j.semcancer.2019.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Jeong JH, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues. Arch Pharm Res 2021;44:1-15. [PMID: 33230600 DOI: 10.1007/s12272-020-01287-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
178 Oliveira S, Pereira SS, Costa MM, Monteiro MP, Pignatelli D. Ang-Tie Angiogenic Pathway Is Distinctively Expressed in Benign and Malignant Adrenocortical Tumors. Int J Mol Sci 2022;23:5579. [PMID: 35628389 DOI: 10.3390/ijms23105579] [Reference Citation Analysis]
179 Zhao H, Chappell JC. Microvascular bioengineering: a focus on pericytes. J Biol Eng 2019;13:26. [PMID: 30984287 DOI: 10.1186/s13036-019-0158-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
180 Liu A, Curran MA. Tumor hypermetabolism confers resistance to immunotherapy. Semin Cancer Biol 2020;65:155-63. [PMID: 31982512 DOI: 10.1016/j.semcancer.2020.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
181 Tabana Y, Moon TC, Siraki A, Elahi S, Barakat K. Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. Expert Opin Ther Targets 2021;25:347-63. [PMID: 34056985 DOI: 10.1080/14728222.2021.1937123] [Reference Citation Analysis]
182 Sweeney PW, d'Esposito A, Walker-Samuel S, Shipley RJ. Modelling the transport of fluid through heterogeneous, whole tumours in silico. PLoS Comput Biol 2019;15:e1006751. [PMID: 31226169 DOI: 10.1371/journal.pcbi.1006751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
183 Liu X, Xu J, Zhang B, Liu J, Liang C, Meng Q, Hua J, Yu X, Shi S. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Mol Cancer 2019;18:184. [PMID: 31831007 DOI: 10.1186/s12943-019-1117-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
184 Schiffmann LM, Bruns CJ, Schmidt T. Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. Front Oncol 2022;12:897927. [PMID: 35664794 DOI: 10.3389/fonc.2022.897927] [Reference Citation Analysis]
185 Li L, Wen Q, Ding R. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. Front Oncol 2022;12:905520. [DOI: 10.3389/fonc.2022.905520] [Reference Citation Analysis]
186 Braunstein LZ, Riaz N. Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine. J Natl Cancer Inst 2020;112:661-2. [PMID: 31665363 DOI: 10.1093/jnci/djz209] [Reference Citation Analysis]
187 Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting CANCER angiogenesis and immune checkpoint networks for improved tumor immunity. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
188 Zoine JT, Knight KA, Fleischer LC, Sutton KS, Goldsmith KC, Doering CB, Spencer HT. Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model. Oncoimmunology 2019;8:1593804. [PMID: 31413905 DOI: 10.1080/2162402X.2019.1593804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
189 Kozin SV. Vascular damage in tumors: a key player in stereotactic radiation therapy? Trends Cancer 2022:S2405-8033(22)00130-3. [PMID: 35835699 DOI: 10.1016/j.trecan.2022.06.002] [Reference Citation Analysis]
190 Chandrakesan P, Panneerselvam J, May R, Weygant N, Qu D, Berry WR, Pitts K, Stanger BZ, Rao CV, Bronze MS, Houchen CW. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Mol Cancer Ther 2020;19:1539-49. [PMID: 32371580 DOI: 10.1158/1535-7163.MCT-19-0776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Eso Y, Seno H. Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:493-5. [PMID: 33906802 DOI: 10.1016/j.hbpd.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol 2020;10:221. [PMID: 32175278 DOI: 10.3389/fonc.2020.00221] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 28.5] [Reference Citation Analysis]
193 Hou B, Zhou L, Wang H, Saeed M, Wang D, Xu Z, Li Y, Yu H. Engineering Stimuli-Activatable Boolean Logic Prodrug Nanoparticles for Combination Cancer Immunotherapy. Adv Mater 2020;32:e1907210. [PMID: 32048361 DOI: 10.1002/adma.201907210] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 30.0] [Reference Citation Analysis]
194 Pérez Regalado S, León J, Feriche B. Therapeutic approach for digestive system cancers and potential implications of exercise under hypoxia condition: what little is known? a narrative review. J Cancer Res Clin Oncol 2022. [PMID: 35157120 DOI: 10.1007/s00432-022-03918-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ruiz de Porras V, Pardo JC, Notario L, Etxaniz O, Font A. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Int J Mol Sci 2021;22:4712. [PMID: 33946818 DOI: 10.3390/ijms22094712] [Reference Citation Analysis]
196 Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams S, Orlicky DJ, Donadi EA, Haugen BR MD, French J. Lenvatinib plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid 2021. [PMID: 34641722 DOI: 10.1089/thy.2021.0371] [Reference Citation Analysis]
197 Voutouri C, Panagi M, Mpekris F, Stylianou A, Michael C, Averkiou MA, Martin JD, Stylianopoulos T. Endothelin Inhibition Potentiates Cancer Immunotherapy Revealing Mechanical Biomarkers Predictive of Response. Adv Therap 2021;4:2000289. [DOI: 10.1002/adtp.202000289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
199 Sun W, Yang J, Liu B, Liu Q, Wang T, Wang Q, Liu M, Li L, Wang Z, Li S, Siebert H, Zhang N. Ketogenic diet inhibits tumor growth by enhancing immune response, attenuating immunosuppression, inhibiting angiogenesis and EMT in CT26 colon tumor allografts mouse model. Journal of Functional Foods 2022;92:105067. [DOI: 10.1016/j.jff.2022.105067] [Reference Citation Analysis]
200 Leong A, Kim M. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. Int J Mol Sci 2020;21:E8689. [PMID: 33217955 DOI: 10.3390/ijms21228689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
201 Basse C, Swalduz A, Levra MG, Girard N, Remon J, Moro-Sibilot D. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. Bull Cancer 2020;107:779-91. [PMID: 32532420 DOI: 10.1016/j.bulcan.2020.04.018] [Reference Citation Analysis]
202 Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, Huang P, Lindeman N, Langer R, Jain RK. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;pii:201815515. [PMID: 30700545 DOI: 10.1073/pnas.1815515116] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 37.7] [Reference Citation Analysis]
203 Zhao L, Ma B, Yang Y, Li T, Han L, Gao Q. Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Front Oncol 2020;10:507. [PMID: 32373522 DOI: 10.3389/fonc.2020.00507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
204 Allen BD, Limoli CL. Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier. Free Radic Biol Med 2022;178:189-201. [PMID: 34875340 DOI: 10.1016/j.freeradbiomed.2021.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
205 Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. Thorac Cancer 2021. [PMID: 34791812 DOI: 10.1111/1759-7714.14236] [Reference Citation Analysis]
206 Mougel A, Terme M, Tanchot C. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Front Immunol 2019;10:467. [PMID: 30923527 DOI: 10.3389/fimmu.2019.00467] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 20.3] [Reference Citation Analysis]
207 Nicoś M, Krawczyk P, Crosetto N, Milanowski J. The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. Front Oncol 2020;10:569202. [PMID: 33344229 DOI: 10.3389/fonc.2020.569202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
208 He J, Li C, Ding L, Huang Y, Yin X, Zhang J, Zhang J, Yao C, Liang M, Pirraco RP, Chen J, Lu Q, Baldridge R, Zhang Y, Wu M, Reis RL, Wang Y. Tumor Targeting Strategies of Smart Fluorescent Nanoparticles and Their Applications in Cancer Diagnosis and Treatment. Adv Mater 2019;31:e1902409. [PMID: 31369176 DOI: 10.1002/adma.201902409] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 30.3] [Reference Citation Analysis]
209 Mao Z, Jiang P, Zhang Y, Li Y, Jia X, Wang Q, Jiao M, Jiang L, Shen Y, Guo H. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis. Cancer Med 2021. [PMID: 34747149 DOI: 10.1002/cam4.4405] [Reference Citation Analysis]
210 Saeed M, Gao J, Shi Y, Lammers T, Yu H. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. Theranostics 2019;9:7981-8000. [PMID: 31754376 DOI: 10.7150/thno.37568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 22.0] [Reference Citation Analysis]
211 Kim DH, Seo J, Na K. pH-Sensitive Carbon Dots for Enhancing Photomediated Antitumor Immunity. Mol Pharmaceutics 2020;17:2532-45. [DOI: 10.1021/acs.molpharmaceut.0c00227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
212 Yu X, Zhu L, Liu J, Xie M, Chen J, Li J. Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther 2020;13:11645-58. [PMID: 33223838 DOI: 10.2147/OTT.S271955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
213 Mpekris F, Panagi M, Voutouri C, Martin JD, Samuel R, Takahashi S, Gotohda N, Suzuki T, Papageorgis P, Demetriou P, Pierides C, Koumas L, Costeas P, Kojima M, Ishii G, Constantinidou A, Kataoka K, Cabral H, Stylianopoulos T. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Adv Sci (Weinh) 2021;8:2001917. [PMID: 33552852 DOI: 10.1002/advs.202001917] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
214 Sun X, Yang Z, Tang Y, Mao S, Xiong P, Wang J, Chen J, Zhang Y, Chen M, Xu L. Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy 2021. [PMID: 34758630 DOI: 10.2217/imt-2021-0057] [Reference Citation Analysis]
215 Treps L, Ager A, Hida K. Editorial: Tumor Vessels as Directors of the Tumor Microenvironment: New Findings, Current Challenges & Perspectives. Front Cell Dev Biol 2022;10:885670. [PMID: 35425768 DOI: 10.3389/fcell.2022.885670] [Reference Citation Analysis]
216 Jiang M, Zhang C, Hu Y, Li T, Yang G, Wang G, Zhu J, Shao C, Hou H, Zhou N, Liu K, Zhang X. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma. Oncologist 2022:oyac136. [PMID: 35857405 DOI: 10.1093/oncolo/oyac136] [Reference Citation Analysis]
217 Hoque MM, Abdelazim H, Jenkins-Houk C, Wright D, Patel BM, Chappell JC. The cerebral microvasculature: Basic and clinical perspectives on stroke and glioma. Microcirculation 2021;28:e12671. [PMID: 33171539 DOI: 10.1111/micc.12671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Liu L, Liu Y, Gong L, Zhang M, Wu W. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther 2020;21:983-9. [PMID: 33092443 DOI: 10.1080/15384047.2020.1829265] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Huang B, Hu J, Li H, Luo M, Chen S, Zhang M, Sun Z, Cui R. Near-Infrared IIb Emitting Nanoprobe for High-Resolution Real-Time Imaging-Guided Photothermal Therapy Triggering Enhanced Anti-tumor Immunity. ACS Appl Bio Mater 2020;3:1636-45. [DOI: 10.1021/acsabm.9b01202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
220 Stühler V, Rausch S, Maas JM, Stenzl A, Bedke J. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. Expert Opin Biol Ther 2021;:1-12. [PMID: 33576709 DOI: 10.1080/14712598.2021.1890713] [Reference Citation Analysis]
221 Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol 2021;17:755-7. [PMID: 33508960 DOI: 10.2217/fon-2020-0986] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
222 Zhu D, Li Y, Zhang Z, Xue Z, Hua Z, Luo X, Zhao T, Lu C, Liu Y. Recent advances of nanotechnology-based tumor vessel-targeting strategies. J Nanobiotechnology 2021;19:435. [PMID: 34930293 DOI: 10.1186/s12951-021-01190-y] [Reference Citation Analysis]
223 Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol 2020;15:11-24. [PMID: 31786718 DOI: 10.1007/s11523-019-00690-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
224 Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. Drug Des Devel Ther 2020;14:275-84. [PMID: 32158186 DOI: 10.2147/DDDT.S227477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
225 Kudo M. Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer 2019;8:413-26. [PMID: 32479569 DOI: 10.1159/000503254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
226 Jain S, Chalif EJ, Aghi MK. Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. Front Oncol 2021;11:812916. [PMID: 35096619 DOI: 10.3389/fonc.2021.812916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
227 Cai X, Wei B, Li L, Chen X, Liu W, Cui J, Lin Y, Sun Y, Xu Q, Guo W, Gu Y. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Int Immunopharmacol 2020;88:106858. [PMID: 32795895 DOI: 10.1016/j.intimp.2020.106858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
228 Mateus PAM, Kido LA, Silva RS, Cagnon VHA, Montico F. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice. Prostate 2019;79:515-35. [PMID: 30585351 DOI: 10.1002/pros.23758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
229 Bui QL, Mas L, Hollebecque A, Tougeron D, de la Fouchardière C, Pudlarz T, Alouani E, Guimbaud R, Taieb J, André T, Colle R, Cohen R. Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. Cancers 2022;14:406. [DOI: 10.3390/cancers14020406] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Duru G, van Egmond M, Heemskerk N. A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Front Immunol 2020;11:584723. [PMID: 33262763 DOI: 10.3389/fimmu.2020.584723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
231 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
232 Franchi-Mendes T, Eduardo R, Domenici G, Brito C. 3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment. Cancers (Basel) 2021;13:4610. [PMID: 34572836 DOI: 10.3390/cancers13184610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
233 Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book 2019;39:147-64. [PMID: 31099674 DOI: 10.1200/EDBK_240837] [Cited by in Crossref: 187] [Cited by in F6Publishing: 129] [Article Influence: 62.3] [Reference Citation Analysis]
234 Liberini V, Mariniello A, Righi L, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandreis D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel) 2021;13:4543. [PMID: 34572771 DOI: 10.3390/cancers13184543] [Reference Citation Analysis]
235 Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14:e0212513. [PMID: 30811474 DOI: 10.1371/journal.pone.0212513] [Cited by in Crossref: 84] [Cited by in F6Publishing: 95] [Article Influence: 28.0] [Reference Citation Analysis]
236 Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clin Cancer Res 2020;26:4268-79. [PMID: 32398324 DOI: 10.1158/1078-0432.CCR-20-0056] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 16.5] [Reference Citation Analysis]
237 An D, Banerjee S, Lee JM. Recent advancements of antiangiogenic combination therapies in ovarian cancer. Cancer Treat Rev 2021;98:102224. [PMID: 34051628 DOI: 10.1016/j.ctrv.2021.102224] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Alanazi MM, Aldawas S, Elwan A, Elkady H. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1093-114. [PMID: 34056992 DOI: 10.1080/14756366.2021.1915303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
239 Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother 2022. [PMID: 35347395 DOI: 10.1007/s00262-022-03185-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Guo L, Zhang J, Liu X, Liu H, Zhang Y, Liu J. Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OTT 2022;Volume 15:629-36. [DOI: 10.2147/ott.s346635] [Reference Citation Analysis]
241 Lee J, Kim SE, Moon D, Doh J. A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues. Lab Chip 2021;21:2142-52. [PMID: 33913456 DOI: 10.1039/d1lc00182e] [Reference Citation Analysis]
242 Chen JL, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL, Kuo SH, Shieh MJ. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother 2021;70:391-404. [PMID: 32761424 DOI: 10.1007/s00262-020-02690-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
243 Sorenson L, Fu Y, Hood T, Warren S, McEachron TA. Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma. Oncoimmunology 2019;8:e1629779. [PMID: 31428529 DOI: 10.1080/2162402X.2019.1629779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, Chen Q, Xie S, Liu A, Yin S, Xu Z, Lu X. Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. Int J Nanomedicine 2021;16:2337-56. [PMID: 33790553 DOI: 10.2147/IJN.S297631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Fischer JR, Buchner H, Kitzing T, Kaiser R, Radonjic D, Kerr K. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. Lung Cancer 2020;148:159-65. [PMID: 32927350 DOI: 10.1016/j.lungcan.2020.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Rong L, Lei Q, Zhang XZ. Engineering Living Bacteria for Cancer Therapy. ACS Appl Bio Mater 2020;3:8136-45. [PMID: 35019596 DOI: 10.1021/acsabm.0c01286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
247 De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? Cancers (Basel) 2021;13:2040. [PMID: 33922556 DOI: 10.3390/cancers13092040] [Reference Citation Analysis]
248 Hua X, Zhu X. [Research Advances of Ang-2 in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:868-74. [PMID: 30454550 DOI: 10.3779/j.issn.1009-3419.2018.11.09] [Reference Citation Analysis]
249 Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat 2020;53:100718. [PMID: 32736034 DOI: 10.1016/j.drup.2020.100718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
250 Kim C, Lim M, Woodworth GF, Arvanitis CD. The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors. J Neurooncol 2022. [PMID: 35235137 DOI: 10.1007/s11060-022-03973-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Kudo M. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 2020;9:119-37. [PMID: 32399427 DOI: 10.1159/000505189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
252 Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? Clin Cancer Res 2020;26:5287-96. [PMID: 32527943 DOI: 10.1158/1078-0432.CCR-20-1135] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
253 Amin A, Hammers H. The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma. Front Immunol 2018;9:3120. [PMID: 30687324 DOI: 10.3389/fimmu.2018.03120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
254 Chen Y, Zhang J, Zhou C, Liu J, Liu S, Shi H, Zu Q. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis. JHC 2022;Volume 9:685-94. [DOI: 10.2147/jhc.s373250] [Reference Citation Analysis]
255 Wirsching HG, Roth P, Weller M. A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opin Ther Targets 2021;25:87-100. [PMID: 33482697 DOI: 10.1080/14728222.2021.1881062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
256 Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00378-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
257 Yousaf I, Kaeppler J, Frost S, Seymour LW, Jacobus EJ. Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion. Cancers (Basel) 2020;12:E851. [PMID: 32244697 DOI: 10.3390/cancers12040851] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
258 de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. Eur Urol Oncol 2019;2:505-14. [PMID: 31377308 DOI: 10.1016/j.euo.2019.06.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
259 Ding K, Zheng Z, Han Y, Huang X. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. Cell Cycle 2022;:1-17. [PMID: 35894701 DOI: 10.1080/15384101.2022.2103898] [Reference Citation Analysis]
260 Kudo M. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1089. [PMID: 32349374 DOI: 10.3390/cancers12051089] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
261 Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine 2019;48:191-202. [PMID: 31648983 DOI: 10.1016/j.ebiom.2019.09.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
262 Hooglugt A, van der Stoel MM, Boon RA, Huveneers S. Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Front Oncol 2020;10:612802. [PMID: 33614496 DOI: 10.3389/fonc.2020.612802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
263 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
264 Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C, Gu Y, Jiang Y. Bidirectional Crosstalk between Therapeutic Cancer Vaccines and the Tumor Microenvironment: Beyond Tumor Antigens. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.03.009] [Reference Citation Analysis]
265 Majidpoor J, Mortezaee K. Steps in metastasis: an updated review. Med Oncol 2021;38:3. [PMID: 33394200 DOI: 10.1007/s12032-020-01447-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
266 Newport EL, Pedrosa AR, Njegic A, Hodivala-Dilke KM, Muñoz-Félix JM. Improved Immunotherapy Efficacy by Vascular Modulation. Cancers (Basel) 2021;13:5207. [PMID: 34680355 DOI: 10.3390/cancers13205207] [Reference Citation Analysis]
267 He P, Zhou W, Liu M, Chen Y. Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy. Curr Top Med Chem 2019;19:1464-83. [PMID: 31264549 DOI: 10.2174/1568026619666190628115644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
268 Lang JE, Tseng WW, Kang I. Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2. Ann Surg Oncol 2019;26:4188-90. [PMID: 31502016 DOI: 10.1245/s10434-019-07801-1] [Reference Citation Analysis]
269 Saeed A, Park R, Sun W. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol 2021;14:13. [PMID: 33436042 DOI: 10.1186/s13045-021-01034-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
270 Tang S, Ning Q, Yang L, Mo Z, Tang S. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol 2020;86:106700. [PMID: 32590316 DOI: 10.1016/j.intimp.2020.106700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
271 Han C, Ye S, Hu C, Shen L, Qin Q, Bai Y, Yang S, Bai C, Zang A, Jiao S, Bai L. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Front Oncol 2021;11:684867. [PMID: 34327136 DOI: 10.3389/fonc.2021.684867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Feng H, Zhao Y, Yan W, Wei X, Lin J, Jiang P, Wang C, Li B. Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning. Front Med 2022;9:843749. [DOI: 10.3389/fmed.2022.843749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Yang Z, Gao D, Guo X, Jin L, Zheng J, Wang Y, Chen S, Zheng X, Zeng L, Guo M, Zhang X, Tian Z. Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets. ACS Nano 2020. [PMID: 33166111 DOI: 10.1021/acsnano.0c07721] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 39.0] [Reference Citation Analysis]
274 Giatromanolaki A, Kouroupi M, Kontomanolis EN, Koukourakis MI. Regulatory tumor-infiltrating lymphocytes prevail in endometrial tumors with low vascular survival ability. Immunobiology 2021;226:152078. [PMID: 33725493 DOI: 10.1016/j.imbio.2021.152078] [Reference Citation Analysis]
275 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 50.0] [Reference Citation Analysis]
276 Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Semin Radiat Oncol 2020;30:129-38. [PMID: 32381292 DOI: 10.1016/j.semradonc.2019.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
277 Bilska M, Pawłowska A, Zakrzewska E, Chudzik A, Suszczyk D, Gogacz M, Wertel I. Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy. Journal of Oncology 2020;2020:1-15. [DOI: 10.1155/2020/8797683] [Reference Citation Analysis]
278 Arend RC, Jackson-Fisher A, Jacobs IA, Chou J, Monk BJ. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Cancer Biol Ther 2021;22:89-105. [PMID: 33427569 DOI: 10.1080/15384047.2020.1868937] [Reference Citation Analysis]
279 Zhu L, Liu J, Chen J, Zhou Q. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. J Hematol Oncol 2021;14:206. [PMID: 34930377 DOI: 10.1186/s13045-021-01218-8] [Reference Citation Analysis]
280 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
281 Zafar A, Hasan M, Tariq T, Dai Z. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies. Bioconjug Chem 2021. [PMID: 34793138 DOI: 10.1021/acs.bioconjchem.1c00437] [Reference Citation Analysis]
282 Chung SW, Xie Y, Suk JS. Overcoming physical stromal barriers to cancer immunotherapy. Drug Deliv Transl Res 2021. [PMID: 34351575 DOI: 10.1007/s13346-021-01036-y] [Reference Citation Analysis]
283 Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, Lugano R, Miller EN, Fujiwara Y, Bian L, Zheng L, Anand S, Gao F, Zhang W, Ferrara SE, Goodspeed AE, Dimberg A, Wang XJ, Edil BH, Barnett CC, Schulick RD, Chen L, Zhu Y. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sci Transl Med 2021;13:eabc8922. [PMID: 34321321 DOI: 10.1126/scitranslmed.abc8922] [Reference Citation Analysis]
284 Robillard L, Liao M, Nguyen M, Harding TC, Simmons AD, Dusek RL. The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. J Immunother 2022. [PMID: 35791438 DOI: 10.1097/CJI.0000000000000427] [Reference Citation Analysis]
285 Zhang Y, Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukocyte Bio. [DOI: 10.1002/jlb.5ru0222-082r] [Reference Citation Analysis]
286 Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35633441 DOI: 10.1007/s10147-022-02174-0] [Reference Citation Analysis]
287 Benavente S, Sánchez-García A, Naches S, LLeonart ME, Lorente J. Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Front Oncol 2020;10:582884. [PMID: 33194719 DOI: 10.3389/fonc.2020.582884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
288 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
289 Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cell Oncol (Dordr) 2021;44:715-37. [PMID: 33835425 DOI: 10.1007/s13402-021-00602-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
290 Xie P, Guo L, Zhang B, Xu Y, Song Q, Shi H, Ye Q, Li H, Xiao Y. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Front Oncol 2022;12:911202. [DOI: 10.3389/fonc.2022.911202] [Reference Citation Analysis]
291 Seano G, Jain RK. Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis 2020;23:9-16. [PMID: 31679081 DOI: 10.1007/s10456-019-09691-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
292 Wang X, Dou X, Ren X, Rong Z, Sun L, Deng Y, Chen P, Li Z. A Ductal-Cell-Related Risk Model Integrating Single-Cell and Bulk Sequencing Data Predicts the Prognosis of Patients With Pancreatic Adenocarcinoma. Front Genet 2021;12:763636. [PMID: 35047000 DOI: 10.3389/fgene.2021.763636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Li S, Wu X, Yan X, Zhou L, Chi Z, Si L, Cui C, Tang B, Mao L, Lian B, Wang X, Bai X, Dai J, Kong Y, Tang X, Feng H, Yao S, Flaherty KT, Guo J, Sheng X. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer 2022;10:e004036. [PMID: 35193932 DOI: 10.1136/jitc-2021-004036] [Reference Citation Analysis]
294 Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020;9:E675. [PMID: 32138216 DOI: 10.3390/jcm9030675] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
295 Carlino F, Diana A, Piccolo A, Ventriglia A, Bruno V, De Santo I, Letizia O, De Vita F, Daniele B, Ciardiello F, Orditura M. Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. Cancers (Basel) 2022;14:2102. [PMID: 35565233 DOI: 10.3390/cancers14092102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
296 Butters O, Young K, Cunningham D, Chau I, Starling N. Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. Front Oncol 2019;9:618. [PMID: 31380271 DOI: 10.3389/fonc.2019.00618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
297 Monaco L, Gemelli M, Gotuzzo I, Bauckneht M, Crivellaro C, Genova C, Cortinovis D, Zullo L, Ammoni LC, Bernasconi DP, Rossi G, Morbelli S, Guerra L. Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. Cancers (Basel) 2021;13:1634. [PMID: 33915801 DOI: 10.3390/cancers13071634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
298 Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H. Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers (Basel) 2020;12:E3630. [PMID: 33291555 DOI: 10.3390/cancers12123630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
299 Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First-Line Management of Advanced High-Grade Serous Ovarian Cancer. Curr Oncol Rep 2020;22:64. [PMID: 32494876 DOI: 10.1007/s11912-020-00933-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
300 Min AKT, Mimura K, Nakajima S, Okayama H, Saito K, Sakamoto W, Fujita S, Endo H, Saito M, Saze Z, Momma T, Ohki S, Kono K. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer. Cancer Immunol Immunother 2021;70:289-98. [PMID: 32705303 DOI: 10.1007/s00262-020-02676-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Personeni N, Pressiani T, Rimassa L. Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Sci Rep 2020;3:e147. [PMID: 32166192 DOI: 10.1002/hsr2.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
302 Liu Z, Wang Y, Huang Y, Kim BYS, Shan H, Wu D, Jiang W. Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends Pharmacol Sci 2019;40:613-23. [PMID: 31331639 DOI: 10.1016/j.tips.2019.07.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
303 Shan W, Zheng H, Fu G, Liu C, Li Z, Ye Y, Zhao J, Xu D, Sun L, Wang X, Chen XL, Bi S, Ren L, Fu G. Bioengineered Nanocage from HBc Protein for Combination Cancer Immunotherapy. Nano Lett 2019;19:1719-27. [DOI: 10.1021/acs.nanolett.8b04722] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
304 Hall MR, Dehbi HM, Banerjee S, Lord R, Clamp A, Ledermann JA, Nicum S, Lilleywhite R, Bowen R, Michael A, Feeney A, Glasspool R, Hackshaw A, Rustin G. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2020;159:692-8. [PMID: 33077258 DOI: 10.1016/j.ygyno.2020.09.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
305 Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert SM, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst 2021;113:532-42. [PMID: 33146385 DOI: 10.1093/jnci/djaa174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, Meng L, Xin Y, Jiang X. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res 2021;40:24. [PMID: 33422072 DOI: 10.1186/s13046-020-01820-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
307 Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo B, Colomer R, Apala JV, Blanco R, Muñoz M, Caleiras E, Iranzo V, Martinez M, Dominguez O, Hornedo J, Gonzalez-Cortijo L, Cortes J, Gasol Cudos A, Malon D, Lopez-Alonso A, Moreno-Ortíz MC, Mouron S, Mañes S. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res 2020;22:124. [PMID: 33176887 DOI: 10.1186/s13058-020-01362-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
308 Amoozgar Z, Jain RK, Duda DG. Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System? Cancer Res 2019;79:2104-6. [PMID: 31043429 DOI: 10.1158/0008-5472.CAN-19-0749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
309 Li Y, Jiang M, Deng Z, Zeng S, Hao J. Low Dose Soft X-Ray Remotely Triggered Lanthanide Nanovaccine for Deep Tissue CO Gas Release and Activation of Systemic Anti-Tumor Immunoresponse. Adv Sci (Weinh) 2021;8:e2004391. [PMID: 34165903 DOI: 10.1002/advs.202004391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
310 Liu ZL, Zhu LL, Liu JH, Pu ZY, Ruan ZP, Chen J. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging (Albany NY) 2020;12:25172-88. [PMID: 33223512 DOI: 10.18632/aging.104119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
311 Guo MZ, Marrone KA, Spira A, Scott SC. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review. Cancer J 2021;27:476-81. [PMID: 34904810 DOI: 10.1097/PPO.0000000000000555] [Reference Citation Analysis]
312 Lin D, Feng X, Mai B, Li X, Wang F, Liu J, Liu X, Zhang K, Wang X. Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery. Biomaterials 2021;277:121124. [PMID: 34534860 DOI: 10.1016/j.biomaterials.2021.121124] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 García-Martínez E, Redondo A, Piulats JM, Rodríguez A, Casado A. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer? Angiogenesis 2020;23:543-57. [PMID: 32691290 DOI: 10.1007/s10456-020-09734-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
314 Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian Cancer Immunotherapy: Turning up the Heat. Int J Mol Sci 2019;20:E2927. [PMID: 31208030 DOI: 10.3390/ijms20122927] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 19.0] [Reference Citation Analysis]
315 Mortezaee K. Immune escape: A critical hallmark in solid tumors. Life Sci 2020;258:118110. [PMID: 32698074 DOI: 10.1016/j.lfs.2020.118110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
316 Lei J, Zhang D, Yao C, Ding S, Lu Z. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. Cancer Control. 2020;27:1073274820977114. [PMID: 33269615 DOI: 10.1177/1073274820977114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
317 Zhang T, Lin R, Wu H, Jiang X, Gao J. Mesenchymal stem cells: A living carrier for active tumor-targeted delivery. Adv Drug Deliv Rev 2022;185:114300. [PMID: 35447165 DOI: 10.1016/j.addr.2022.114300] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Hu R, Zeng Q, Su X, Feng W, Xiang H. The Correlation between Targeted Contrast-Enhanced Ultrasound Imaging and Tumor Neovascularization of Ovarian Cancer Xenografts in Nude Mice. J Healthc Eng 2021;2021:5553649. [PMID: 33815730 DOI: 10.1155/2021/5553649] [Reference Citation Analysis]
319 Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 2022;15:83. [PMID: 35765040 DOI: 10.1186/s13045-022-01305-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Xu Z, Hao X, Yang K, Wang Q, Wang J, Lin L, Teng F, Li J, Xing P. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. J Cancer Res Clin Oncol 2022. [PMID: 34982222 DOI: 10.1007/s00432-021-03901-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li GL, Wang PX, Wu SB, Duan JX, Zhuo WF, Liu PQ, Min J. Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal 2020;18:46. [PMID: 32183816 DOI: 10.1186/s12964-020-00535-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
322 Cui Q, Hu Y, Ma D, Liu H. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. Drug Des Devel Ther 2021;15:339-47. [PMID: 33536747 DOI: 10.2147/DDDT.S286529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
323 Murphy AD, Morgan RD, Clamp AR, Jayson GC. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. Br J Cancer 2021. [PMID: 34716396 DOI: 10.1038/s41416-021-01605-5] [Reference Citation Analysis]
324 Abdalla AME, Xiao L, Miao Y, Huang L, Fadlallah GM, Gauthier M, Ouyang C, Yang G. Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer. Adv Sci (Weinh) 2020;7:1903164. [PMID: 32440473 DOI: 10.1002/advs.201903164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
325 Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med. 2020;45:279-297. [PMID: 31894255 DOI: 10.3892/ijmm.2019.4418] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
326 Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu T, Wang X, Chu T, Huang Y, Xu W, Qin S. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol 2022;13:937924. [DOI: 10.3389/fimmu.2022.937924] [Reference Citation Analysis]
327 Huang L, Zhao H, Shan M, Chen H, Xu B, He Y, Zhao Y, Liu Z, Chen J, Xu Q. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med 2022. [PMID: 35762456 DOI: 10.1002/cam4.4845] [Reference Citation Analysis]
328 Ni K, Xu Z, Culbert A, Luo T, Guo N, Yang K, Pearson E, Preusser B, Wu T, La Riviere P, Weichselbaum RR, Spiotto MT, Lin W. Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework. Nat Biomed Eng. [DOI: 10.1038/s41551-022-00846-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
329 Huang Q, Lei Y, Li X, Guo F, Liu M. A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance. Front Cell Dev Biol 2020;8:580140. [PMID: 33344447 DOI: 10.3389/fcell.2020.580140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
330 Li H, Huang H, Zhang T, Feng H, Wang S, Zhang Y, Ji X, Cheng X, Zhao R. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. Front Immunol 2022;13:937307. [DOI: 10.3389/fimmu.2022.937307] [Reference Citation Analysis]
331 Galmiche A, Rak J, Roumenina LT, Saidak Z. Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer 2022:S2405-8033(21)00261-2. [PMID: 35027336 DOI: 10.1016/j.trecan.2021.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
332 Chen M, Yang S, Fan L, Wu L, Chen R, Chang J, Hu J. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report. Pancreas 2019;48:1232-6. [PMID: 31609933 DOI: 10.1097/MPA.0000000000001398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
333 Wang EJ, Chen JS, Jain S, Morshed RA, Haddad AF, Gill S, Beniwal AS, Aghi MK. Immunotherapy Resistance in Glioblastoma. Front Genet 2021;12:750675. [PMID: 34976006 DOI: 10.3389/fgene.2021.750675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Shi Y, Li Y, Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Lv C, Han S, Yu Y, Xu F, Tian Y. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. Int Immunopharmacol 2022;110:108968. [PMID: 35764018 DOI: 10.1016/j.intimp.2022.108968] [Reference Citation Analysis]
335 Zheng D, Hou X, Yu J, He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol 2022;13:928369. [DOI: 10.3389/fphar.2022.928369] [Reference Citation Analysis]
336 Too NSH, Ho NCW, Adine C, Iyer NG, Fong ELS. Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models. Adv Drug Deliv Rev 2021;175:113791. [PMID: 33965462 DOI: 10.1016/j.addr.2021.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
337 Ukidve A, Cu K, Kumbhojkar N, Lahann J, Mitragotri S. Overcoming biological barriers to improve solid tumor immunotherapy. Drug Deliv Transl Res 2021. [PMID: 33611770 DOI: 10.1007/s13346-021-00923-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Huang Y, Chen Y, Zhou S, Chen L, Wang J, Pei Y, Xu M, Feng J, Jiang T, Liang K, Liu S, Song Q, Jiang G, Gu X, Zhang Q, Gao X, Chen J. Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat Commun 2020;11:622. [PMID: 32001695 DOI: 10.1038/s41467-020-14425-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
339 Yuan J, Li X, Yu S. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. Cancer Control 2021;28:10732748211038424. [PMID: 34844463 DOI: 10.1177/10732748211038424] [Reference Citation Analysis]
340 Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers (Basel) 2021;13:1795. [PMID: 33918704 DOI: 10.3390/cancers13081795] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 28.0] [Reference Citation Analysis]
341 Tian Y, Sang W, Tian H, Xie L, Wang G, Zhang Z, Li W, Dai Y. A Two‐Step Flexible Ultrasound Strategy to Enhance the Tumor Radiotherapy via Metal–Phenolic Network Nanoplatform. Adv Funct Materials. [DOI: 10.1002/adfm.202205690] [Reference Citation Analysis]
342 Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabé R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer 2021:S1525-7304(21)00189-3. [PMID: 34393061 DOI: 10.1016/j.cllc.2021.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
343 How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers 2022;14:3695. [DOI: 10.3390/cancers14153695] [Reference Citation Analysis]
344 Heraudet L, Delon T, Veillon R, Vergnenègre C, Lepetit H, Daste A, Ravaud A, Zysman M, Domblides C. Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study. Thoracic Cancer. [DOI: 10.1111/1759-7714.14403] [Reference Citation Analysis]
345 Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug Deliv Transl Res 2021. [PMID: 34176099 DOI: 10.1007/s13346-021-01018-0] [Reference Citation Analysis]
346 Wen X, Wu Y, Tanaka Y, Awadasseid A, Tao H, Zhang W. Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma. Life Sci 2021;269:119066. [PMID: 33460663 DOI: 10.1016/j.lfs.2021.119066] [Reference Citation Analysis]
347 Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol 2021;7:1051-9. [PMID: 33885725 DOI: 10.1001/jamaoncol.2021.0168] [Reference Citation Analysis]
348 Mei K, Qin S, Chen Z, Liu Y, Wang L, Zou J. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer 2021;9:e002191. [PMID: 33741732 DOI: 10.1136/jitc-2020-002191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
349 Li S, Chen L. Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma. Front Oncol 2022;12:793432. [PMID: 35155236 DOI: 10.3389/fonc.2022.793432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Katoh M. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clin Sci (Lond). 2019;133:953-970. [PMID: 31036756 DOI: 10.1042/cs20180845] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
351 Lan C, Shen J, Wang Y, Li J, Liu Z, He M, Cao X, Ling J, Huang J, Zheng M, Zou G, Yan H, Liu Q, Yang F, Wei W, Deng Y, Xiong Y, Huang X. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol 2020;38:4095-106. [PMID: 33052760 DOI: 10.1200/JCO.20.01920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
352 Atanasov G, Dino K, Schierle K, Dietel C, Aust G, Pratschke J, Seehofer D, Schmelzle M, Hau HM. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis. World J Surg Oncol 2019;17:217. [PMID: 31830991 DOI: 10.1186/s12957-019-1756-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
353 Liu J, Liew SS, Wang J, Pu K. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. Adv Mater 2022;34:e2103790. [PMID: 34651344 DOI: 10.1002/adma.202103790] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
354 Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res 2021;27:1048-57. [PMID: 33199490 DOI: 10.1158/1078-0432.CCR-20-2500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
355 Andreuzzi E, Fejza A, Capuano A, Poletto E, Pivetta E, Doliana R, Pellicani R, Favero A, Maiero S, Fornasarig M, Cannizzaro R, Iozzo RV, Spessotto P, Mongiat M. Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis. Matrix Biol Plus 2020;6-7:100029. [PMID: 33543026 DOI: 10.1016/j.mbplus.2020.100029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
356 Lee J, Chang JS, Roh MR, Jung M, Lee CK, Oh BH, Chung KY, Koom WS, Shin SJ. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. Cancer Res Treat 2020;52:730-8. [PMID: 32054150 DOI: 10.4143/crt.2019.598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
357 Feng X, Wei Z, Zhang S, Du Y, Zhao H. A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors. Front Oncol 2019;9:937. [PMID: 31850188 DOI: 10.3389/fonc.2019.00937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
358 Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM, Pomper MG, Banerjee SR. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. Nanotheranostics 2021;5:182-96. [PMID: 33564617 DOI: 10.7150/ntno.52361] [Reference Citation Analysis]
359 Tormoen GW, Crittenden MR, Gough MJ. Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol 2018;3:520-6. [PMID: 30370351 DOI: 10.1016/j.adro.2018.08.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
360 Delprat V, Michiels C. A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression. Cancer Metastasis Rev 2021;40:477-500. [PMID: 33783686 DOI: 10.1007/s10555-021-09958-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Li X, Fan Y, Zhang Y, Wang Y, Zhao M, Tang M, Li H, Mi J, Geng Z, Wang Z, Su F. CHSY3 can be a Poor Prognostic Biomarker and Mediates Immune Evasion in Stomach Adenocarcinoma. Front Genet 2022;13:876588. [DOI: 10.3389/fgene.2022.876588] [Reference Citation Analysis]
362 You Y, Guo X, Zhuang R, Zhang C, Wang Z, Shen F, Wang Y, Liu W, Zhang Y, Lu W, Hou Y, Wang J, Zhang X, Lu M, Zhou Y. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis. Front Mol Biosci 2021;8:747650. [PMID: 34869583 DOI: 10.3389/fmolb.2021.747650] [Reference Citation Analysis]
363 Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 2018;21:425-532. [PMID: 29766399 DOI: 10.1007/s10456-018-9613-x] [Cited by in Crossref: 206] [Cited by in F6Publishing: 224] [Article Influence: 68.7] [Reference Citation Analysis]
364 Gilmore E, McCabe N, Kennedy RD, Parkes EE. DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. J Oncol 2019;2019:4325105. [PMID: 31320901 DOI: 10.1155/2019/4325105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
365 Paganetti H. Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02684-5. [PMID: 34407443 DOI: 10.1016/j.ijrobp.2021.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
366 Zhang Q, Liu X, Wei S, Zhang L, Tian Y, Gao Z, Jin M, Yan S. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Front Oncol 2021;11:751391. [PMID: 34900698 DOI: 10.3389/fonc.2021.751391] [Reference Citation Analysis]
367 Wu X, Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bulletin du Cancer 2019;106:946-58. [DOI: 10.1016/j.bulcan.2019.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
368 Xie H, Wang W, Qi W, Jin W, Xia B. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application. Front Immunol 2021;12:661115. [PMID: 34712221 DOI: 10.3389/fimmu.2021.661115] [Reference Citation Analysis]
369 Grohé C, Blau W, Gleiber W, Haas S, Hammerschmidt S, Krüger S, Müller-Huesmann H, Schulze M, Wehler T, Atz J, Kaiser R. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study. Clin Oncol (R Coll Radiol) 2022:S0936-6555(21)00491-X. [PMID: 35012901 DOI: 10.1016/j.clon.2021.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
370 Feng B, Hou B, Xu Z, Saeed M, Yu H, Li Y. Self-Amplified Drug Delivery with Light-Inducible Nanocargoes to Enhance Cancer Immunotherapy. Adv Mater 2019;31:e1902960. [PMID: 31423683 DOI: 10.1002/adma.201902960] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 37.0] [Reference Citation Analysis]
371 Nakano S, Eso Y, Okada H, Takai A, Takahashi K, Seno H. Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E775. [PMID: 32218257 DOI: 10.3390/cancers12040775] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
372 Toyokuni S. Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention. Free Radical Biology and Medicine 2019;133:206-15. [DOI: 10.1016/j.freeradbiomed.2018.10.401] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
373 Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 2019;8:E1602. [PMID: 31835465 DOI: 10.3390/cells8121602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
374 Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int 2021;21:262. [PMID: 33985527 DOI: 10.1186/s12935-021-01972-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
375 Li Z, Deng J, Sun J, Ma Y. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors. Front Immunol 2020;11:595207. [PMID: 33240283 DOI: 10.3389/fimmu.2020.595207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
376 Ding M, Kong X, Chen W, Yan L, Huang H, Lv Z, Jiang P, Mu A, Huang C, Shi J. Efficient starvation therapy with three-pathway blocking in combination with PTT/CDT for TME reversal and tumor apoptosis. Journal of Industrial and Engineering Chemistry 2022;110:456-70. [DOI: 10.1016/j.jiec.2022.03.022] [Reference Citation Analysis]
377 Zhou Q, Dong C, Fan W, Jiang H, Xiang J, Qiu N, Piao Y, Xie T, Luo Y, Li Z, Liu F, Shen Y. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy. Biomaterials 2020;240:119902. [PMID: 32105817 DOI: 10.1016/j.biomaterials.2020.119902] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 21.5] [Reference Citation Analysis]
378 Zhu C, Gu L, Liu Z, Li J, Yao M, Fang C. Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma. BMC Cancer 2021;21:836. [PMID: 34284746 DOI: 10.1186/s12885-021-08547-4] [Reference Citation Analysis]
379 Wu D, Nie J, Hu W, Dai L, Zhang J, Chen X, Ma X, Tian G, Han J, Han S, Long J, Wang Y, Zhang Z, Fang J. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer 2020;147:3453-60. [PMID: 32557583 DOI: 10.1002/ijc.33161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
380 Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X. Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol 2021;11:719836. [PMID: 34476218 DOI: 10.3389/fonc.2021.719836] [Reference Citation Analysis]
381 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
382 Zhou Y, Fu C, Kong Y, Pan D, Wang Y, Huang S, Li Z, Ning Z, Lu X, Shan S, Xin L. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anticancer Drugs 2019;30:909-16. [PMID: 30998512 DOI: 10.1097/CAD.0000000000000791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
383 Wuyts SC, Schoffelen R, Westdorp H, van Erp NP. Dose finding of oncolytic combination therapy: Essential to secure the patient's quality of life. Eur J Cancer 2021:S0959-8049(21)00480-9. [PMID: 34420835 DOI: 10.1016/j.ejca.2021.07.022] [Reference Citation Analysis]
384 Zhou C, Liu Q, Xiang Y, Gou X, Li W. Role of the tumor immune microenvironment in tumor immunotherapy. Oncol Lett 2022;23:53. [PMID: 34992685 DOI: 10.3892/ol.2021.13171] [Reference Citation Analysis]
385 Lamb LS, Sim HW, McCormack AI. Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne) 2020;11:576027. [PMID: 33312158 DOI: 10.3389/fendo.2020.576027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
386 Zhu Y, Yu X, Thamphiwatana SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharm Sin B 2020;10:2054-74. [PMID: 33304779 DOI: 10.1016/j.apsb.2020.08.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
387 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
388 Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, Chen ZS, Ye W, Zhang D. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resist Updat 2022;64:100849. [PMID: 35842983 DOI: 10.1016/j.drup.2022.100849] [Reference Citation Analysis]
389 Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 2021;24:697-717. [PMID: 33820953 DOI: 10.1038/s41391-021-00340-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
390 Hayashi SI, Rakugi H, Morishita R. Insight into the Role of Angiopoietins in Ageing-Associated Diseases. Cells 2020;9:E2636. [PMID: 33302426 DOI: 10.3390/cells9122636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
391 Mediratta K, El-Sahli S, D'Costa V, Wang L. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E3529. [PMID: 33256070 DOI: 10.3390/cancers12123529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
392 Wen H, Fei Y, Cai R, Yao X, Li Y, Wang X, Xue C, Hu Y, Li M, Luo Z. Tumor-activatable biomineralized nanotherapeutics for integrative glucose starvation and sensitized metformin therapy. Biomaterials 2021;278:121165. [PMID: 34649197 DOI: 10.1016/j.biomaterials.2021.121165] [Reference Citation Analysis]
393 Chen S, Huang Y, Chen M, Hung Y, Lee R, Shao Y, Chao Y. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09173-4] [Reference Citation Analysis]
394 Elaldi R, Hemon P, Petti L, Cosson E, Desrues B, Sudaka A, Poissonnet G, Van Obberghen-Schilling E, Pers JO, Braud VM, Anjuère F, Meghraoui-Kheddar A. High Dimensional Imaging Mass Cytometry Panel to Visualize the Tumor Immune Microenvironment Contexture. Front Immunol 2021;12:666233. [PMID: 33936105 DOI: 10.3389/fimmu.2021.666233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
395 Dai Z, Wang Q, Tang J, Wu M, Li H, Yang Y, Zhen X, Yu C. Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy. Biomaterials 2021;:121261. [PMID: 34815099 DOI: 10.1016/j.biomaterials.2021.121261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
396 Li G, Jiang Y. Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Front Oncol 2022;12:916790. [DOI: 10.3389/fonc.2022.916790] [Reference Citation Analysis]
397 Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res 2022. [PMID: 35759090 DOI: 10.1007/s12272-022-01389-z] [Reference Citation Analysis]
398 Wu C, Cui M, Cai L, Chen C, Zhu X, Wu Y, Liu J, Wang H, Zhang Y. NIR-Responsive Photodynamic Nanosystem Combined with Antitumor Immune Optogenetics Bacteria for Precise Synergetic Therapy. ACS Appl Mater Interfaces 2022;14:13094-106. [PMID: 35262323 DOI: 10.1021/acsami.2c01138] [Reference Citation Analysis]
399 Li Z, Di C, Li S, Yang X, Nie G. Smart Nanotherapeutic Targeting of Tumor Vasculature. Acc Chem Res 2019;52:2703-12. [PMID: 31433171 DOI: 10.1021/acs.accounts.9b00283] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 25.0] [Reference Citation Analysis]
400 Martin JD, Duda DG, Jain RK. Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer? Circ Res 2020;127:724-6. [PMID: 32853096 DOI: 10.1161/CIRCRESAHA.120.317720] [Reference Citation Analysis]
401 Cantelmo AR, Dejos C, Kocher F, Hilbe W, Wolf D, Pircher A. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. Curr Opin Oncol 2020;32:44-53. [PMID: 31609741 DOI: 10.1097/CCO.0000000000000591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
402 Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Biomarker-driven immunotherapy for precision medicine in prostate cancer. Per Med 2022;19:51-66. [PMID: 34873959 DOI: 10.2217/pme-2021-0079] [Reference Citation Analysis]
403 Shi Y. PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity. J Control Release 2021;339:156-63. [PMID: 34563591 DOI: 10.1016/j.jconrel.2021.09.028] [Reference Citation Analysis]
404 Teng Y, Ding X, Li W, Sun W, Chen J. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338221075174. [PMID: 35313780 DOI: 10.1177/15330338221075174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
405 Zhang T, Merle P, Wang H, Zhao H, Kudo M. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. [PMID: 33898559 DOI: 10.21037/hbsn-2021-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248-1264. [PMID: 30849371 DOI: 10.1016/j.cell.2019.01.021] [Cited by in Crossref: 352] [Cited by in F6Publishing: 357] [Article Influence: 176.0] [Reference Citation Analysis]
407 Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. [PMID: 30925919 DOI: 10.1186/s12943-019-0974-6] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
408 Li Y, Chen X, Li W, Ye Y, Du X, Sun S, Liu L, Zhang H. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. Front Oncol 2021;11:684309. [PMID: 34109130 DOI: 10.3389/fonc.2021.684309] [Reference Citation Analysis]
409 Ma Z, Zhang X, Xu L, Liu D, Di S, Li W, Zhang J, Zhang H, Li X, Han J, Yan X. Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies. Pharmacological Research 2019;145:104265. [DOI: 10.1016/j.phrs.2019.104265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
410 French JD. Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies. Nat Rev Endocrinol 2020;16:629-41. [PMID: 32839578 DOI: 10.1038/s41574-020-0398-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
411 Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open 2019;2:e192535. [PMID: 31050774 DOI: 10.1001/jamanetworkopen.2019.2535] [Cited by in Crossref: 294] [Cited by in F6Publishing: 254] [Article Influence: 98.0] [Reference Citation Analysis]
412 Deng G, Sun Z, Li S, Peng X, Li W, Zhou L, Ma Y, Gong P, Cai L. Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. ACS Nano 2018;12:12096-108. [PMID: 30444351 DOI: 10.1021/acsnano.8b05292] [Cited by in Crossref: 150] [Cited by in F6Publishing: 134] [Article Influence: 37.5] [Reference Citation Analysis]
413 Nicolini G, Forini F, Kusmic C, Iervasi G, Balzan S. Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci 2019;239:117080. [PMID: 31756341 DOI: 10.1016/j.lfs.2019.117080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
414 Carminati L, Taraboletti G. Thrombospondins in bone remodeling and metastatic bone disease. Am J Physiol Cell Physiol 2020;319:C980-90. [PMID: 32936697 DOI: 10.1152/ajpcell.00383.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Li L, Yang S, Chen Y, Tian L, He Y, Wu B, Dong D. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Pharmacol 2022;13:891008. [PMID: 35721168 DOI: 10.3389/fphar.2022.891008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res 2020;26:804-11. [PMID: 31558480 DOI: 10.1158/1078-0432.CCR-19-1223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
417 Mpekris F, Voutouri C, Baish JW, Duda DG, Munn LL, Stylianopoulos T, Jain RK. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A 2020;117:3728-37. [PMID: 32015113 DOI: 10.1073/pnas.1919764117] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 30.0] [Reference Citation Analysis]
418 Tiek DM, Cheng SY. New life for an old therapy: ELTD1 as a downstream target of angiogenesis. Neuro Oncol 2022:noab286. [PMID: 35015881 DOI: 10.1093/neuonc/noab286] [Reference Citation Analysis]
419 Wang Y, Chen L, Yu M, Fang Y, Qian K, Wang G, Ju L, Xiao Y, Wang X. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Med 2020;9:7729-41. [PMID: 32841548 DOI: 10.1002/cam4.3400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
420 Munn LL, Stylianopoulos T, Jain NK, Hardin CC, Khandekar MJ, Jain RK. Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer. Clin Cancer Res 2021;27:2706-11. [PMID: 33648989 DOI: 10.1158/1078-0432.CCR-20-4750] [Reference Citation Analysis]
421 Chen Y, Bai B, Ying K, Pan H, Xie B. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188775] [Reference Citation Analysis]
422 de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? Am Soc Clin Oncol Educ Book 2020;40:1-18. [PMID: 32343604 DOI: 10.1200/EDBK_278853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
423 Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
424 Welsh M. Perspectives on Vascular Regulation of Mechanisms Controlling Selective Immune Cell Function in the Tumor Immune Response. Int J Mol Sci 2022;23:2313. [PMID: 35216427 DOI: 10.3390/ijms23042313] [Reference Citation Analysis]
425 Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer 2020;6:10. [PMID: 32195333 DOI: 10.1038/s41523-020-0153-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
426 Popat S, Grohé C, Corral J, Reck M, Novello S, Gottfried M, Radonjic D, Kaiser R. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? Lung Cancer 2020;144:76-84. [PMID: 32387684 DOI: 10.1016/j.lungcan.2020.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
427 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Reference Citation Analysis]
428 Ayuso-Íñigo B, Méndez-García L, Pericacho M, Muñoz-Félix JM. The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement? Cancers (Basel) 2021;13:5412. [PMID: 34771575 DOI: 10.3390/cancers13215412] [Reference Citation Analysis]
429 Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med 2019;9:E84. [PMID: 31905724 DOI: 10.3390/jcm9010084] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 23.0] [Reference Citation Analysis]
430 Pyo DH, Hong HK, Lee WY, Cho YB. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line. Cancer Biol Ther 2020;21:495-502. [PMID: 32208894 DOI: 10.1080/15384047.2020.1738907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
431 Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021;184:5309-37. [PMID: 34624224 DOI: 10.1016/j.cell.2021.09.020] [Reference Citation Analysis]
432 Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca EA, Weissleder R, Kantarci AG, Tannous BA. Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano 2019;13:4028-40. [PMID: 30916923 DOI: 10.1021/acsnano.8b08177] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 27.3] [Reference Citation Analysis]
433 Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 2021;18:527-40. [PMID: 33833434 DOI: 10.1038/s41571-021-00496-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
434 Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, Wang Y, Graus Porta D, Chow P, Chung A. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology 2019;69:943-58. [PMID: 30575985 DOI: 10.1002/hep.30481] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
435 Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. npj Breast Cancer 2020;6. [DOI: 10.1038/s41523-020-0153-3] [Reference Citation Analysis]
436 Tanaka I, Furukawa T, Morise M. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell Int 2021;21:454. [PMID: 34446006 DOI: 10.1186/s12935-021-02165-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 Leskelä RL, Peltonen E, Haavisto I, Herse F, Korhonen S, Nolvi K, Käkelä S, Autere AM, Tiainen S, Silvoniemi M, Junnila EL, Ahvonen J, Knuuttila A, Koivunen J. Trends in treatment of non-small cell lung cancer in Finland 2014-2019. Acta Oncol 2022;61:641-8. [PMID: 35411839 DOI: 10.1080/0284186X.2022.2042474] [Reference Citation Analysis]
438 Xie S, Wu Z, Qi Y, Wu B, Zhu X. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother 2021;138:111450. [PMID: 33690088 DOI: 10.1016/j.biopha.2021.111450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
439 Zheng X, Liu Y, Liu Y, Zhang T, Zhao Y, Zang J, Yang Y, He R, Chong G, Ruan S, Xu D, Li Y, Dong H. Dual Closed-Loop of Catalyzed Lactate Depletion and Immune Response to Potentiate Photothermal Immunotherapy. ACS Appl Mater Interfaces 2022. [PMID: 35578899 DOI: 10.1021/acsami.2c07254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Masuda T, Nonami A, Tanaka F, Ando Y, Eto M, Mimori K. A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer. Breast J 2020;26:2420-3. [PMID: 33277749 DOI: 10.1111/tbj.14108] [Reference Citation Analysis]
441 Shen Y, Wang X, Lu J, Salfenmoser M, Wirsik NM, Schleussner N, Imle A, Freire Valls A, Radhakrishnan P, Liang J, Wang G, Muley T, Schneider M, Ruiz de Almodovar C, Diz-Muñoz A, Schmidt T. Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell 2020;37:800-817.e7. [PMID: 32516590 DOI: 10.1016/j.ccell.2020.05.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 21.5] [Reference Citation Analysis]
442 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 2021;54:e13009. [PMID: 33655556 DOI: 10.1111/cpr.13009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
444 Li S, Zhang Q, Hong Y. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy. Technol Cancer Res Treat 2020;19:1533033820980116. [PMID: 33287656 DOI: 10.1177/1533033820980116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
445 Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J, Yu Y. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:653358. [PMID: 33746989 DOI: 10.3389/fimmu.2021.653358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
446 Pirouzpanah S, Asemani S, Shayanfar A, Baradaran B, Montazeri V. The effects of Berberis vulgaris consumption on plasma levels of IGF-1, IGFBPs, PPAR-γ and the expression of angiogenic genes in women with benign breast disease: a randomized controlled clinical trial. BMC Complement Altern Med 2019;19:324. [PMID: 31752829 DOI: 10.1186/s12906-019-2715-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
447 Lefler DS, Snook AE, Bashir B. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. Immunotherapy 2022. [PMID: 35694998 DOI: 10.2217/imt-2022-0012] [Reference Citation Analysis]
448 Cetin B, Gumusay O. Understanding relevant immune mechanisms in gastrointestinal oncology. J Oncol Pharm Pract 2021;27:1222-34. [PMID: 33557689 DOI: 10.1177/1078155221992862] [Reference Citation Analysis]
449 Castet F, Garcia-Mulero S, Sanz-Pamplona R, Cuellar A, Casanovas O, Caminal JM, Piulats JM. Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope? Cancers (Basel) 2019;11:E834. [PMID: 31212986 DOI: 10.3390/cancers11060834] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
450 Guo H, Bai R, Cui J. [Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:101-10. [PMID: 32093454 DOI: 10.3779/j.issn.1009-3419.2020.02.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
451 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 98.0] [Reference Citation Analysis]
452 Chen Q, He Y, Wang Y, Li C, Zhang Y, Guo Q, Zhang Y, Chu Y, Liu P, Chen H, Zhou Z, Zhou W, Zhao Z, Li X, Sun T, Jiang C. Penetrable Nanoplatform for "Cold" Tumor Immune Microenvironment Reeducation. Adv Sci (Weinh) 2020;7:2000411. [PMID: 32995118 DOI: 10.1002/advs.202000411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
453 Voutouri C, Kirkpatrick ND, Chung E, Mpekris F, Baish JW, Munn LL, Fukumura D, Stylianopoulos T, Jain RK. Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies. Proc Natl Acad Sci U S A 2019;116:2662-71. [PMID: 30700544 DOI: 10.1073/pnas.1818322116] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
454 Luo M, Liu Y, Liu N, Shao W, Ming L, Liu J, Xie Y. Proscillaridin A inhibits hepatocellular carcinoma progression through inducing mitochondrial damage and autophagy. Acta Biochim Biophys Sin (Shanghai) 2021;53:19-28. [PMID: 33201987 DOI: 10.1093/abbs/gmaa139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
455 Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Clin Cancer Res 2022;28:2807-17. [PMID: 35247906 DOI: 10.1158/1078-0432.CCR-21-4313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
456 Zeng H, Kang S, Zhang Y, Liu K, Yu Q, Li D, An LK. Synthesis and Biological Evaluation of Oleanolic Acid Derivatives as Selective Vascular Endothelial Growth Factor Promoter i-Motif Ligands. Int J Mol Sci 2021;22:1711. [PMID: 33567767 DOI: 10.3390/ijms22041711] [Reference Citation Analysis]
457 Xu H, Chen X, Huang Z. Identification of ESM1 overexpressed in head and neck squamous cell carcinoma. Cancer Cell Int 2019;19:118. [PMID: 31073279 DOI: 10.1186/s12935-019-0833-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
458 Huynh H, Prawira A, Le TBU, Vu TC, Hao HX, Huang A, Wang Y, Porta DG. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Exp Mol Med 2020;52:1857-68. [PMID: 33235319 DOI: 10.1038/s12276-020-00524-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
459 Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer 2021;9:e002242. [PMID: 34301813 DOI: 10.1136/jitc-2020-002242] [Reference Citation Analysis]
460 Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 2019;14:e0212513. [PMID: 30811474 DOI: 10.1371/journal.pone.0212513] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
461 Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis 2020;23:55-74. [PMID: 31865479 DOI: 10.1007/s10456-019-09698-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
462 Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Reference Citation Analysis]
463 Metzenmacher M, Rizzo F, Kambartel K, Panse J, Schaufler D, Scheffler M, Azeh I, Hoiczyk M, Turki AT, Atz J, Buchner H, Hoffmann C, C Christoph D. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncol 2021. [PMID: 34287064 DOI: 10.2217/fon-2021-0424] [Reference Citation Analysis]
464 Huijbers EJM, Khan KA, Kerbel RS, Griffioen AW. Tumors resurrect an embryonic vascular program to escape immunity. Sci Immunol 2022;7:eabm6388. [PMID: 35030032 DOI: 10.1126/sciimmunol.abm6388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
465 Zheng J, Gao P. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther 2019;18:1534735419862352. [PMID: 31282197 DOI: 10.1177/1534735419862352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
466 von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy SA. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? Int J Mol Sci 2022;23:2569. [PMID: 35269712 DOI: 10.3390/ijms23052569] [Reference Citation Analysis]
467 Guo Y, Guo H, Zhang Y, Cui J. Anaplastic lymphoma kinase-special immunity and immunotherapy. Front Immunol 2022;13:908894. [DOI: 10.3389/fimmu.2022.908894] [Reference Citation Analysis]
468 Guan Q, Li Y, Li W, Dong Y. Photodynamic Therapy Based on Nanoscale Metal-Organic Frameworks: From Material Design to Cancer Nanotherapeutics. Chem Asian J 2018;13:3122-49. [DOI: 10.1002/asia.201801221] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
469 Bao R, Wang Y, Lai J, Zhu H, Zhao Y, Li S, Li N, Huang J, Yang Z, Wang F, Liu Z. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Mol Pharm 2019;16:339-48. [PMID: 30452269 DOI: 10.1021/acs.molpharmaceut.8b00997] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
470 Padda SK, Reckamp KL. Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach. J Thorac Oncol 2021;16:178-82. [PMID: 33494922 DOI: 10.1016/j.jtho.2020.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
471 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
472 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
473 Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev 2019;38:573-94. [PMID: 31828566 DOI: 10.1007/s10555-019-09819-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
474 Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 2019;19:9-31. [PMID: 30532012 DOI: 10.1038/s41568-018-0081-9] [Cited by in Crossref: 225] [Cited by in F6Publishing: 238] [Article Influence: 75.0] [Reference Citation Analysis]
475 Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res 2019;25:4644-55. [PMID: 31061067 DOI: 10.1158/1078-0432.CCR-19-0173] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
476 Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book 2019;39:165-74. [PMID: 31099649 DOI: 10.1200/EDBK_237987] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
477 Chen C, Zhang S, Zhang R, Sun P, Shi C, Abdalla M, Li A, Xu J, Du W, Zhang J, Liu Y, Tang C, Yang Z, Jiang X. In situ tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor. Theranostics 2020;10:11998-2010. [PMID: 33204325 DOI: 10.7150/thno.50806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
478 AbouAitah K, Hassan HA, Swiderska-Sroda A, Gohar L, Shaker OG, Wojnarowicz J, Opalinska A, Smalc-Koziorowska J, Gierlotka S, Lojkowski W. Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles. Cancers (Basel) 2020;12:E144. [PMID: 31936103 DOI: 10.3390/cancers12010144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
479 Zhen Z, Shen Z, Hu Y, Sun P. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis. Aging (Albany NY) 2021;13:17707-33. [PMID: 34252885 DOI: 10.18632/aging.203260] [Reference Citation Analysis]
480 Tan AC, Pavlakis N. Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC). IJMS 2022;23:8863. [DOI: 10.3390/ijms23168863] [Reference Citation Analysis]
481 Morisaki T, Kashiwagi S, Asano Y, Goto W, Takada K, Ishihara S, Shibutani M, Tanaka H, Hirakawa K, Ohira M. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. World J Surg Oncol 2021;19:324. [PMID: 34775950 DOI: 10.1186/s12957-021-02441-w] [Reference Citation Analysis]
482 Zhao L, Zhang J, Xuan S, Liu Z, Wang Y, Zhao P. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma. Front Cell Dev Biol 2021;9:600506. [PMID: 33614641 DOI: 10.3389/fcell.2021.600506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
483 Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Reference Citation Analysis]
484 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]
485 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
486 Dorst DCHV, Doorn LV, Mirabito Colafella KM, Manintveld OC, Hassing HC, Danser AHJ, Mathijssen RHJ, Versmissen J. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk? Clin Sci (Lond) 2021;135:1649-68. [PMID: 34283204 DOI: 10.1042/CS20200300] [Reference Citation Analysis]
487 Omar HA, El‐serafi AT, Hersi F, Arafa EA, Zaher DM, Madkour M, Arab HH, Tolba MF. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. FEBS J 2019;286:3540-57. [DOI: 10.1111/febs.15000] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
488 Liang T, Tong W, Ma S, Chang P. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. Oncoimmunology 2020;9:1773205. [PMID: 32934878 DOI: 10.1080/2162402X.2020.1773205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
489 Dai X, Ren L, Liu M, Cai H, Zhang H, Gong Q, Gu Z, Luo K. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today 2021;39:101163. [DOI: 10.1016/j.nantod.2021.101163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Murayama Y, Kobayashi K, Kagamu H, Kuji I. Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. J Clin Med 2020;9:E725. [PMID: 32156047 DOI: 10.3390/jcm9030725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
491 Quaresmini D, Guida M. Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment. Front Immunol 2020;11:584903. [PMID: 33193402 DOI: 10.3389/fimmu.2020.584903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
492 Tian H, Wang G, Sang W, Xie L, Zhang Z, Li W, Yan J, Tian Y, Li J, Li B, Dai Y. Manganese-phenolic nanoadjuvant combines sonodynamic therapy with cGAS-STING activation for enhanced cancer immunotherapy. Nano Today 2022;43:101405. [DOI: 10.1016/j.nantod.2022.101405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
493 Lu LC, Chang CJ, Hsu CH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019;6:71-84. [PMID: 31123667 DOI: 10.2147/jhc.s159693] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
494 Mattheolabakis G, Mikelis CM. Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg? Front Oncol 2019;9:1227. [PMID: 31799190 DOI: 10.3389/fonc.2019.01227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
495 Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science 2020;370:eaaz0868. [PMID: 33122355 DOI: 10.1126/science.aaz0868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 26.5] [Reference Citation Analysis]
496 Bagegni NA, Park H, Kraft K, O-Toole M, Gao F, Waqar SN, Ratner L, Morgensztern D, Devarakonda S, Amin M, Baggstrom MQ, Liang C, Selvaggi G, Wang-Gillam A. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemother Pharmacol 2022. [PMID: 35247086 DOI: 10.1007/s00280-022-04406-6] [Reference Citation Analysis]
497 Zander H, Müller-Egert S, Zwiewka M, Groß S, van Zandbergen G, Engelbergs J. [Checkpoint inhibitors for cancer therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1322-30. [PMID: 33001218 DOI: 10.1007/s00103-020-03221-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
498 Jiang P, Geng L, Mao Z, Wang Q, Wang W, Jiao M, Yao Y, Chen N, Zhang J, Nan K, Shen Y, Guo H, Jiang L. First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy 2022. [PMID: 35259921 DOI: 10.2217/imt-2021-0112] [Reference Citation Analysis]
499 Zhou J, Wang L, Peng C, Peng F. Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology. Front Pharmacol 2022;13:886198. [DOI: 10.3389/fphar.2022.886198] [Reference Citation Analysis]
500 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol 2020;17:251-66. [PMID: 32034288 DOI: 10.1038/s41571-019-0308-z] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 62.5] [Reference Citation Analysis]
502 Castellano D, Apolo AB, Porta C, Capdevila J, Viteri S, Rodriguez-antona C, Martin L, Maroto P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Ther Adv Med Oncol 2022;14:175883592211086. [DOI: 10.1177/17588359221108691] [Reference Citation Analysis]
503 Jiang L, Tan X, Li J, Li Y. Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:726008. [PMID: 34712609 DOI: 10.3389/fonc.2021.726008] [Reference Citation Analysis]
504 Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomedicine 2021;16:1631-61. [PMID: 33688183 DOI: 10.2147/IJN.S290346] [Reference Citation Analysis]
505 Cavin S, Gkasti A, Faget J, Hao Y, Letovanec I, Reichenbach M, Gonzalez M, Krueger T, Dyson PJ, Meylan E, Perentes JY. Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma. Eur J Cardiothorac Surg 2020;58:783-91. [PMID: 32372095 DOI: 10.1093/ejcts/ezaa145] [Reference Citation Analysis]
506 Xu P, Yan F, Zhao Y, Chen X, Sun S, Wang Y, Ying L. Green Tea Polyphenol EGCG Attenuates MDSCs-mediated Immunosuppression through Canonical and Non-Canonical Pathways in a 4T1 Murine Breast Cancer Model. Nutrients 2020;12:E1042. [PMID: 32290071 DOI: 10.3390/nu12041042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
507 Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou VA, Socinski MA, Sandler A. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med 2020;14:125-36. [PMID: 31829747 DOI: 10.1080/17476348.2020.1701439] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
508 Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, Llovet JM. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology 2021;74:2652-69. [PMID: 34157147 DOI: 10.1002/hep.32023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
509 Jin C, Yuan M, Bu H, Jin C, Tomao F. Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/4880355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
510 Ngwa VM, Edwards DN, Philip M, Chen J. Microenvironmental Metabolism Regulates Antitumor Immunity. Cancer Res 2019;79:4003-8. [PMID: 31362930 DOI: 10.1158/0008-5472.CAN-19-0617] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
511 Reischer A, Kruger S, von Bergwelt-Baildon M. [A decade of checkpoint inhibitors: current standard of care and future trends]. Dtsch Med Wochenschr 2021;146:1108-18. [PMID: 34448187 DOI: 10.1055/a-1303-8820] [Reference Citation Analysis]
512 Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, Krishnan S, Posada JM, Ghosh M, Mamessier E, Wong C, Ferraro GB, Batista A, Wang N, Badeaux M, Roberge S, Xu L, Huang P, Shalek AK, Fukumura D, Kim HJ, Jain RK. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun 2021;12:2582. [PMID: 33976133 DOI: 10.1038/s41467-021-22885-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
513 Lee SS, Bindokas VP, Lingen MW, Kron SJ. Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. Lab Invest 2019;99:1400-13. [PMID: 30401959 DOI: 10.1038/s41374-018-0156-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
514 Liu SH, Chen PS, Huang CC, Hung YT, Lee MY, Lin WH, Lin YC, Lee AY. Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer. Front Pharmacol 2020;11:601785. [PMID: 33519464 DOI: 10.3389/fphar.2020.601785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
515 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol 2022. [PMID: 35034502 DOI: 10.2217/fon-2021-1096] [Reference Citation Analysis]
517 Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi AL, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, Kolettas E, Batistatou A, Pentheroudakis G. Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. Cancers (Basel) 2020;12:E3145. [PMID: 33121034 DOI: 10.3390/cancers12113145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
518 Yu B, Yoo D, Kim KH, Kim TW, Park S, Kim Y, Son Y, Kim J, Noh I, Whang C, Chung J, Jon S. Effective Combination Immunotherapy through Vessel Normalization Using a Cancer‐Targeting Antiangiogenic Peptide–Antibody Hybrid. Advanced Therapeutics. [DOI: 10.1002/adtp.202100151] [Reference Citation Analysis]
519 Georganaki M, van Hooren L, Dimberg A. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Front Immunol 2018;9:3081. [PMID: 30627131 DOI: 10.3389/fimmu.2018.03081] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
520 Liu J, Chen J, Liu H, Zhang K, Zeng Q, Yang S, Jiang Z, Zhang X, Chen T, Li D, Shan H. Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2021;13:42473-85. [PMID: 34474563 DOI: 10.1021/acsami.1c11763] [Reference Citation Analysis]
521 Yu X, He S, Shen J, Huang Q, Yang P, Huang L, Pu D, Wang L, Li L, Liu J, Liu Z, Zhu L. Tumor vessel normalization and immunotherapy in gastric cancer. Ther Adv Med Oncol 2022;14:17588359221110176. [PMID: 35872968 DOI: 10.1177/17588359221110176] [Reference Citation Analysis]
522 Guo Q, Guan GF, Cao JY, Zou CY, Zhu C, Cheng W, Xu XY, Lin ZG, Cheng P, Wu AH. Overexpression of oncostatin M receptor regulates local immune response in glioblastoma. J Cell Physiol 2019. [PMID: 30693511 DOI: 10.1002/jcp.28197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
523 van Duijn A, Willemsen KJ, van Uden NOP, Hoyng L, Erades S, Koster J, Luiten RM, Bakker WJ. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma. Cancer Immunol Immunother 2021. [PMID: 34268602 DOI: 10.1007/s00262-021-03007-1] [Reference Citation Analysis]
524 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
525 Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C, Wang T, Dong L, Shi M, Qin J, Xue M, Cao Y, Liu J, Liu P, Huang J, Wen C, Zhang J, Xu Z, Bai F, Deng X, Peng C, Chen H, Jiang L, Chen S, Shen B. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 2022:gutjnl-2021-326070. [PMID: 35688610 DOI: 10.1136/gutjnl-2021-326070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology 2020;71:1247-61. [PMID: 31378984 DOI: 10.1002/hep.30889] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 54.0] [Reference Citation Analysis]
527 Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Reference Citation Analysis]
528 Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ, Kim C. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest 2019;129:4350-64. [PMID: 31343989 DOI: 10.1172/JCI125413] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
529 Miranda KM, Ridnour LA, McGinity CL, Bhattacharyya D, Wink DA. Nitric Oxide and Cancer: When to Give and When to Take Away? Inorg Chem 2021;60:15941-7. [PMID: 34694129 DOI: 10.1021/acs.inorgchem.1c02434] [Reference Citation Analysis]
530 Qiang H, Chang Q, Xu J, Qian J, Zhang Y, Lei Y, Han B, Chu T. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2020;146:631-45. [PMID: 32065262 DOI: 10.1007/s00432-020-03129-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
531 Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL. Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat Commun 2021;12:6058. [PMID: 34663816 DOI: 10.1038/s41467-021-26343-3] [Reference Citation Analysis]
532 Eso Y. Targeting Angiogenesis for Advanced Hepatocellular Carcinoma. Intern Med 2021;60:321-2. [PMID: 32963171 DOI: 10.2169/internalmedicine.5923-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Ren S, Xiong X, You H, Shen J, Zhou P. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:689132. [DOI: 10.3389/fimmu.2021.689132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
534 Melo V, Bremer E, Martin JD. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. Front Cell Dev Biol 2022;10:908389. [PMID: 35712656 DOI: 10.3389/fcell.2022.908389] [Reference Citation Analysis]
535 Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2021;7:78-85. [PMID: 33211063 DOI: 10.1001/jamaoncol.2020.5945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
536 Zhang Z, Yang C, Li L, Zhu Y, Su K, Zhai L, Wang Z, Huang J. "γδT Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. Front Immunol 2021;12:699478. [PMID: 34721375 DOI: 10.3389/fimmu.2021.699478] [Reference Citation Analysis]
537 Kampoli K, Foukas PG, Ntavatzikos A, Arkadopoulos N, Koumarianou A. Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World J Methodol 2022; 12(1): 43-53 [DOI: 10.5662/wjm.v12.i1.43] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Gui L, Liu S, Zhang Y, Shi Y. A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. Onco Targets Ther 2021;14:2741-6. [PMID: 33907417 DOI: 10.2147/OTT.S305196] [Reference Citation Analysis]
539 Wang Z, Gong X, Li J, Wang H, Xu X, Li Y, Sha X, Zhang Z. Oxygen-Delivering Polyfluorocarbon Nanovehicles Improve Tumor Oxygenation and Potentiate Photodynamic-Mediated Antitumor Immunity. ACS Nano 2021;15:5405-19. [PMID: 33625842 DOI: 10.1021/acsnano.1c00033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
540 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Reference Citation Analysis]
541 Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer 2021;10:249-59. [PMID: 34239811 DOI: 10.1159/000514420] [Reference Citation Analysis]
542 Ai B, Yang Y. [Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:626-30. [PMID: 32702797 DOI: 10.3779/j.issn.1009-3419.2020.101.34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Peng C, Huang Y, Zheng J. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance. Journal of Controlled Release 2020;322:64-80. [DOI: 10.1016/j.jconrel.2020.03.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
544 Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, Li S, Xue P, Wang G, Sun Y, Du X, Zhang X, Ma Z, Wang J. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. J Thorac Oncol 2021;16:1099-117. [PMID: 33839365 DOI: 10.1016/j.jtho.2021.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Front Immunol 2018;9:3107. [PMID: 30692993 DOI: 10.3389/fimmu.2018.03107] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
546 Wang J, Bo X, Wang C, Xin Y, Nan L, Luo R, Chen L, Shi X, Suo T, Ni X, Liu H, Shen S, Li M, Lu P, Wang Y, Liu H. Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer. Cancer Sci 2020;111:219-28. [PMID: 31729088 DOI: 10.1111/cas.14239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
547 Mougel A, Méjean F, Tran T, Adimi Y, Galy-fauroux I, Kaboré C, Mercier E, Urquia P, Terme M, Tartour E, Tanchot C. Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. OncoImmunology 2022;11:2110218. [DOI: 10.1080/2162402x.2022.2110218] [Reference Citation Analysis]
548 Grohé C, Gleiber W, Haas S, Losem C, Mueller-huesmann H, Schulze M, Franke C, Basara N, Atz J, Kaiser R. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncology 2019;15:2699-706. [DOI: 10.2217/fon-2019-0262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
549 Xie XH, Deng HY, Lin XQ, Wu JH, Liu M, Xie ZH, Qin YY, Zhou CZ. Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer. Front Oncol 2021;11:673877. [PMID: 34221992 DOI: 10.3389/fonc.2021.673877] [Reference Citation Analysis]
550 Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. Future Oncol 2022. [PMID: 35232247 DOI: 10.2217/fon-2021-0862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Jin R, Zhao J, Xia L, Li Q, Li W, Peng L, Xia Y. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Ther Adv Med Oncol 2020;12:1758835920930333. [PMID: 32565926 DOI: 10.1177/1758835920930333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
552 Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 2022;21:84. [PMID: 35337339 DOI: 10.1186/s12943-022-01536-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
553 Huang D, Sun L, Huang L, Chen Y. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. J Pers Med 2021;11:124. [PMID: 33672813 DOI: 10.3390/jpm11020124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
554 Tao Z, Suo H, Zhang L, Jin Z, Wang Z, Wang D, Wu M, Peng N, Zhao Y, Chen B. MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer. Onco Targets Ther 2020;13:12255-68. [PMID: 33273831 DOI: 10.2147/OTT.S263998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q, Yuan W, Luo R, Lu C, Liu R, Gu J, Ge D. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer Immunol Immunother 2022. [PMID: 35278107 DOI: 10.1007/s00262-022-03173-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Peng C, Rabold K, Mulder WJM, Jaeger M, Netea-Maier RT. Kinase Inhibitors' Effects on Innate Immunity in Solid Cancers. Cancers (Basel) 2021;13:5695. [PMID: 34830850 DOI: 10.3390/cancers13225695] [Reference Citation Analysis]
557 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
558 Huang Y, Li W, Quan Q, Zhang B, Yang Q. Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer. J Cancer 2019;10:6858-64. [PMID: 31839820 DOI: 10.7150/jca.31182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
559 Fucà G, de Braud F, Di Nicola M. Immunotherapy-based combinations: an update. Curr Opin Oncol 2018;30:345-51. [PMID: 29994900 DOI: 10.1097/CCO.0000000000000466] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
560 Rinchai D, Verzoni E, Huber V, Cova A, Squarcina P, De Cecco L, de Braud F, Ratta R, Dugo M, Lalli L, Vallacchi V, Rodolfo M, Roelands J, Castelli C, Chaussabel D, Procopio G, Bedognetti D, Rivoltini L. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clin Transl Med 2021;11:e434. [PMID: 34185403 DOI: 10.1002/ctm2.434] [Reference Citation Analysis]
561 Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X, Xu Q. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Front Oncol 2021;11:683502. [PMID: 34692475 DOI: 10.3389/fonc.2021.683502] [Reference Citation Analysis]
562 Adachi Y, Matsuki M, Watanabe H, Takase K, Kodama K, Matsui J, Funahashi Y, Nomoto K. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma. Cancer Invest 2019;37:185-98. [PMID: 31006280 DOI: 10.1080/07357907.2019.1601209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
563 Baraibar I, Roman M, Rodríguez-Remírez M, López I, Vilalta A, Guruceaga E, Ecay M, Collantes M, Lozano T, Alignani D, Puyalto A, Oliver A, Ortiz-Espinosa S, Moreno H, Torregrosa M, Rolfo C, Caglevic C, García-Ros D, Villalba-Esparza M, De Andrea C, Vicent S, Pío R, Lasarte JJ, Calvo A, Ajona D, Gil-Bazo I. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers (Basel) 2020;12:E3169. [PMID: 33126649 DOI: 10.3390/cancers12113169] [Reference Citation Analysis]
564 El-Gazzar MG, El-Hazek RM, Zaher NH, El-Ghazaly MA. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study. Bioorg Chem 2019;92:103251. [PMID: 31525526 DOI: 10.1016/j.bioorg.2019.103251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
565 Lange S, Hultborn R, Jennische E. Antisecretory factor AF-16 improves vascular access to a rat mammary tumour. APMIS 2020;128:387-9. [PMID: 32105360 DOI: 10.1111/apm.13036] [Reference Citation Analysis]
566 Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, Valabrega G. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. Int J Mol Sci 2020;21:E4414. [PMID: 32575899 DOI: 10.3390/ijms21124414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
567 Wan J, Wang J, Zhou M, Rao Z, Ling X. A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells. J Mater Chem B 2020;8:7755-65. [PMID: 32735004 DOI: 10.1039/d0tb01052a] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
568 Zhang L, Zhang M, Wang L, Li J, Yang T, Shao Q, Liang X, Ma M, Zhang N, Jing M, Song R, Fan J. Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:694664. [PMID: 34900664 DOI: 10.3389/fonc.2021.694664] [Reference Citation Analysis]
569 Martínez-Poveda B, Torres-Vargas JA, Ocaña MDC, García-Caballero M, Medina MÁ, Quesada AR. The Mediterranean Diet, a Rich Source of Angiopreventive Compounds in Cancer. Nutrients 2019;11:E2036. [PMID: 31480406 DOI: 10.3390/nu11092036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
570 Klein S, Duda DG. Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers (Basel) 2021;13:4919. [PMID: 34638408 DOI: 10.3390/cancers13194919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
571 Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ, Shao ZM. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol 2021;14:98. [PMID: 34172088 DOI: 10.1186/s13045-021-01103-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
572 Wu J, Zhao X, Sun Q, Jiang Y, Zhang W, Luo J, Li Y. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother 2020;125:109746. [PMID: 32106386 DOI: 10.1016/j.biopha.2019.109746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
573 Chen Y. First-line combination immunotherapy for metastatic non-small cell lung cancer. Journal of the Chinese Medical Association 2020;83:433-41. [DOI: 10.1097/jcma.0000000000000287] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
574 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
575 Kaneda T, Kurata T, Yoshida T, Kibata K, Yoshioka H, Yanagimoto H, Takeda K, Yoshida T, Tsuta K. Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. BMC Cancer 2022;22:154. [PMID: 35135489 DOI: 10.1186/s12885-022-09264-2] [Reference Citation Analysis]
576 [DOI: 10.1101/2021.04.12.438457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
577 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
578 Zhao Y, Liu T, Zhou M. Immune-Cell-Derived Exosomes for Cancer Therapy. Mol Pharm 2022. [PMID: 35876318 DOI: 10.1021/acs.molpharmaceut.2c00407] [Reference Citation Analysis]
579 Santaniello A, Napolitano F, Servetto A, De Placido P, Silvestris N, Bianco C, Formisano L, Bianco R. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers (Basel) 2019;11:E1419. [PMID: 31554160 DOI: 10.3390/cancers11101419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
580 Seliger B. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Front Immunol 2019;10:999. [PMID: 31178856 DOI: 10.3389/fimmu.2019.00999] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
581 O’connor MN, Kallenberg DM, Camilli C, Pilotti C, Dritsoula A, Jackstadt R, Bowers CE, Watson HA, Alatsatianos M, Ohme J, Dowsett L, George J, Blackburn JW, Wang X, Singhal M, Augustin HG, Ager A, Sansom OJ, Moss SE, Greenwood J. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med 2021;2:1231-1252.e10. [DOI: 10.1016/j.medj.2021.10.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
582 Yuan J, Yuan B, Zeng L, Liu B, Chen Y, Meng X, Sun R, Lv X, Wang W, Yang S. Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma. Oncol Lett 2020;20:1772-80. [PMID: 32724420 DOI: 10.3892/ol.2020.11735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Kasakovski D, Skrygan M, Gambichler T, Susok L. Advances in Targeting Cutaneous Melanoma. Cancers (Basel) 2021;13:2090. [PMID: 33925915 DOI: 10.3390/cancers13092090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
584 Liu C, Shao J, Dong Y, Xu Q, Zou Z, Chen F, Yan J, Liu J, Li S, Liu B, Shen J. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report. Front Immunol 2021;12:685126. [PMID: 34326839 DOI: 10.3389/fimmu.2021.685126] [Reference Citation Analysis]
585 Li W, Zhan M, Quan Y, Wang H, Hua S, Li Y, Zhang J, Lu L, Cui M. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy. International Immunopharmacology 2020;81:106227. [DOI: 10.1016/j.intimp.2020.106227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
586 Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer 2020;122:1732-43. [PMID: 32327707 DOI: 10.1038/s41416-020-0834-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
587 Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 2020;52:1475-85. [PMID: 32913278 DOI: 10.1038/s12276-020-00500-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 20.5] [Reference Citation Analysis]
588 Xu Z, Li J. [Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:357-64. [PMID: 34034460 DOI: 10.3779/j.issn.1009-3419.2021.101.16] [Reference Citation Analysis]
589 Filippi R, Lombardi P, Quarà V, Fenocchio E, Aimar G, Milanesio M, Leone F, Aglietta M. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opin Pharmacother 2019;20:2121-37. [PMID: 31550186 DOI: 10.1080/14656566.2019.1667335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
590 Claesson-Welsh L. How the matrix metalloproteinase MMP14 contributes to the progression of colorectal cancer. J Clin Invest 2020;130:1093-5. [PMID: 32015228 DOI: 10.1172/JCI135239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
591 Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov 2019;9:1349-57. [PMID: 31527133 DOI: 10.1158/2159-8290.CD-19-0499] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
592 García-Mulero S, Alonso MH, Del Carpio LP, Sanz-Pamplona R, Piulats JM. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. Int J Mol Sci 2021;22:2669. [PMID: 33800878 DOI: 10.3390/ijms22052669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
593 Wang L, Sun X, He J, Liu Z. Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma. Front Oncol 2022;12:781686. [DOI: 10.3389/fonc.2022.781686] [Reference Citation Analysis]
594 Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia Signaling in Cancer: From Basics to Clinical Practice. Pathol Oncol Res 2021;27:1609802. [PMID: 34257622 DOI: 10.3389/pore.2021.1609802] [Reference Citation Analysis]
595 Hahn A, Bode J, Alexander A, Karimian-Jazi K, Schregel K, Schwarz D, Sommerkamp AC, Krüwel T, Abdollahi A, Wick W, Platten M, Bendszus M, Tews B, Kurz FT, Breckwoldt MO. Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. J Cereb Blood Flow Metab 2021;41:1536-46. [PMID: 33043767 DOI: 10.1177/0271678X20961854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
596 Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer 2020;8:e001435. [PMID: 33234602 DOI: 10.1136/jitc-2020-001435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
597 Gu M, Xu T, Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol 2021;13:17588359211006950. [PMID: 33995590 DOI: 10.1177/17588359211006950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
598 Martin-Liberal J, Hollebecque A, Aftimos P, Jungels C, Martin-Romano P, Rodon J, Kremer JD, Zhang W, Bendell J. First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. Br J Cancer 2020;123:1235-43. [PMID: 32741971 DOI: 10.1038/s41416-020-1011-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 Ge Y, Yoon S, Jang H, Jeong J, Lee Y. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment. Phytomedicine 2020;78:153318. [DOI: 10.1016/j.phymed.2020.153318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
600 Li J, Zhang X, Mu Z, Sun D, Sun Y, Lin Y. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review. Front Immunol 2022;13:943916. [DOI: 10.3389/fimmu.2022.943916] [Reference Citation Analysis]
601 Malkova AM, Sharoyko VV, Zhukova NV, Gubal AR, Orlova RV. Laboratory biomarkers of an effective antitumor immune response. Clinical significance. Cancer Treat Res Commun 2021;29:100489. [PMID: 34837797 DOI: 10.1016/j.ctarc.2021.100489] [Reference Citation Analysis]
602 Gen S, Tanaka I, Morise M, Koyama J, Kodama Y, Matsui A, Miyazawa A, Hase T, Hibino Y, Yokoyama T, Kimura T, Yoshida N, Sato M, Hashimoto N. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer 2022;22:654. [PMID: 35698083 DOI: 10.1186/s12885-022-09741-8] [Reference Citation Analysis]
603 Inoue M, Kim M, Inoue T, Tait M, Byrne T, Nitschké M, Murer P, Cha H, Subramanian A, De Silva N, Chiaverotti T, McDonald DM. Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. Mol Ther Oncolytics 2022;24:299-318. [PMID: 35118189 DOI: 10.1016/j.omto.2021.12.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
604 Wen S, Zhang K, Li Y, Fan J, Ziming C, Zhang J, Wang H, Wang L. A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis. Chinese Chemical Letters 2020;31:3153-7. [DOI: 10.1016/j.cclet.2020.03.077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
605 Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 2021;17:2243-56. [PMID: 33663220 DOI: 10.2217/fon-2020-1290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
606 Wang Z, Sun C, Wu H, Xie J, Zhang T, Li Y, Xu X, Wang P, Wang C. Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer. Mater Today Bio 2022;13:100189. [PMID: 34977528 DOI: 10.1016/j.mtbio.2021.100189] [Reference Citation Analysis]
607 Liu ZL, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol 2021;13:17588359211018026. [PMID: 34104226 DOI: 10.1177/17588359211018026] [Reference Citation Analysis]
608 Zhang T, Yu H, Dai X, Zhang X. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Front Immunol 2022;13:971428. [DOI: 10.3389/fimmu.2022.971428] [Reference Citation Analysis]
609 Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20:e175-e186. [PMID: 30842061 DOI: 10.1016/s1470-2045(19)30026-9] [Cited by in Crossref: 122] [Cited by in F6Publishing: 79] [Article Influence: 61.0] [Reference Citation Analysis]
610 Krishnan S, Amoozgar Z, Fukumura D, Jain RK. Implications of a granulocyte-high glioblastoma microenvironment in immune suppression and therapy resistance. J Pathol 2021;254:105-8. [PMID: 33534142 DOI: 10.1002/path.5637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Jones D. Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy. Cells 2020;9:E762. [PMID: 32244922 DOI: 10.3390/cells9030762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
612 Chen B, Gao A, Tu B, Wang Y, Yu X, Wang Y, Xiu Y, Wang B, Wan Y, Huang Y. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials 2020;255:120187. [PMID: 32590192 DOI: 10.1016/j.biomaterials.2020.120187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
613 Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev 2019;290:6-23. [PMID: 31355494 DOI: 10.1111/imr.12766] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 33.0] [Reference Citation Analysis]
614 Chen J, Duda DG. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. EBioMedicine 2020;52:102644. [PMID: 32014823 DOI: 10.1016/j.ebiom.2020.102644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
615 Wang X, He Q, Shen H, Xia A, Tian W, Yu W, Sun B. TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. J Hepatol 2019;71:731-41. [PMID: 31173813 DOI: 10.1016/j.jhep.2019.05.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 26.3] [Reference Citation Analysis]
616 Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
617 Abdul Pari AA, Singhal M, Augustin HG. Emerging paradigms in metastasis research. J Exp Med 2021;218:e20190218. [PMID: 33601416 DOI: 10.1084/jem.20190218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
618 Gupta N, Lampert E, Lee JM. Carving a niche for immunotherapy in ovarian cancer. Oncotarget 2021;12:4-7. [PMID: 33456707 DOI: 10.18632/oncotarget.27864] [Reference Citation Analysis]
619 Cui TM, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11725-40. [PMID: 33235462 DOI: 10.2147/OTT.S279858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
620 Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 2021;33:e12943. [PMID: 33724586 DOI: 10.1111/jne.12943] [Reference Citation Analysis]
621 Liu Z, Zhao Q, Zheng Z, Liu S, Meng L, Dong L, Jiang X. Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. Biomed Pharmacother 2021;139:111607. [PMID: 33965730 DOI: 10.1016/j.biopha.2021.111607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
622 Lai H, Zeng D, Liu C, Zhang Q, Wang X, Chen T. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling. Biomaterials 2019;219:119377. [DOI: 10.1016/j.biomaterials.2019.119377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
623 Zhou C, Zhang J. Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Front Med 2019;13:12-23. [PMID: 30796606 DOI: 10.1007/s11684-019-0685-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
624 Shan Y, Ni Q, Zhang Q, Zhang M, Wei B, Cheng L, Zhong C, Wang X, Wang Q, Liu J, Zhang J, Wu J, Wang G, Zhou F. Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment. Acta Pharmaceutica Sinica B 2022;12:1825-39. [DOI: 10.1016/j.apsb.2022.02.014] [Reference Citation Analysis]
625 Zhou S, Xie J, Huang Z, Deng L, Wu L, Yu J, Meng X. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Cancer Lett 2021;502:166-79. [PMID: 33450361 DOI: 10.1016/j.canlet.2020.12.043] [Reference Citation Analysis]
626 Bourhis M, Palle J, Galy-Fauroux I, Terme M. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Front Immunol 2021;12:616837. [PMID: 33854498 DOI: 10.3389/fimmu.2021.616837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
627 Spagnuolo A, Palazzolo G, Sementa C, Gridelli C. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 2020;21:491-506. [DOI: 10.1080/14656566.2020.1713092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
628 Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q, Shan J, Ruan J. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 2022;22:73. [PMID: 35148789 DOI: 10.1186/s12935-021-02435-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
629 He X, Yang L, Su H, Lin S, Qi D, Chen H, Qu Y, Liu L, Feng X. Clickable amino acid derivative tuned self-assembly of antigen and adjuvant for cancer immunotherapy. J Control Release 2021;337:306-16. [PMID: 34311025 DOI: 10.1016/j.jconrel.2021.07.033] [Reference Citation Analysis]
630 Peng Y, Yu H, Jin Y, Qu F, Ren H, Tang Z, Zhang Y, Qu C, Zong B, Liu S. Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer. Front Immunol 2021;12:666137. [PMID: 33986754 DOI: 10.3389/fimmu.2021.666137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
631 Bilska M, Pawłowska A, Zakrzewska E, Chudzik A, Suszczyk D, Gogacz M, Wertel I. Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy. J Oncol 2020;2020:8797683. [PMID: 32148497 DOI: 10.1155/2020/8797683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
632 Virchow I, Grünwald V. [Current treatment options for recurrent/metastatic renal cell carcinoma (mRCC)]. Aktuelle Urol 2021;52:439-44. [PMID: 34428826 DOI: 10.1055/a-1480-3653] [Reference Citation Analysis]
633 Bilger G, Toffart A, Darrason M, Duruisseaux M, Ulmer L, Wang P, Leprieur EG, Girard N, Massiani MA, Bore P, Descourt R, Pinsolle J, Valery S, Monnet I, Swalduz A, Tissot C, Fournel P, Baranzelli A, Cortot AB, Decroisette C. Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. Ther Adv Med Oncol 2022;14:175883592210993. [DOI: 10.1177/17588359221099399] [Reference Citation Analysis]
634 Yao Y, Zhou X, Zhang A, Ma X, Zhu H, Yang Z, Li N. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. European Journal of Radiology 2022;149:110200. [DOI: 10.1016/j.ejrad.2022.110200] [Reference Citation Analysis]
635 Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med 2021;13:e08253. [PMID: 34125494 DOI: 10.15252/emmm.201708253] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
636 Lv B, Chen J, Liu XL. Anlotinib-Induced Hypertension: Current Concepts and Future Prospects. Curr Pharm Des 2021. [PMID: 34620054 DOI: 10.2174/1381612827666211006145141] [Reference Citation Analysis]
637 Liu X, Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res 2020;8:69. [PMID: 33292551 DOI: 10.1186/s40364-020-00250-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
638 Fitzgerald G, Soro-Arnaiz I, De Bock K. The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer. Front Cell Dev Biol 2018;6:100. [PMID: 30255018 DOI: 10.3389/fcell.2018.00100] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
639 Kabir AU, Subramanian M, Lee DH, Wang X, Krchma K, Wu J, Naismith T, Halabi CM, Kim JY, Pulous FE, Petrich BG, Kim S, Park HC, Hanson PI, Pan H, Wickline SA, Fremont DH, Park C, Choi K. Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity. Sci Transl Med 2021;13:eabb6731. [PMID: 33658356 DOI: 10.1126/scitranslmed.abb6731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
640 Pei P, Zhang Y, Jiang Y, Shen W, Chen H, Yang S, Zhang Y, Yi X, Yang K. Pleiotropic Immunomodulatory Functions of Radioactive Inactivated Bacterial Vectors for Enhanced Cancer Radio-immunotherapy. ACS Nano 2022. [PMID: 35819107 DOI: 10.1021/acsnano.2c04982] [Reference Citation Analysis]